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“The whole of medicine depends on the transparent report‑
ing of clinical trials.”1
Well designed and properly executed randomised con‑
trolled trials (RCTs) provide the most reliable evidence on 
the efficacy of healthcare interventions, but trials with 
inadequate methods are associated with bias, especially 
exaggerated treatment effects.2‑5 Biased results from poorly 
designed and reported trials can mislead decision making 
in health care at all levels, from treatment decisions for a 
patient to formulation of national public health policies.
Critical appraisal of the quality of clinical trials is possible 
only if the design, conduct, and analysis of RCTs are thor‑
oughly and accurately described in the report. Far from being 
transparent, the reporting of RCTs is often incomplete,6‑9 com‑
pounding problems arising from poor methodology.10‑15
incomplete and inaccurate reporting
Many reviews have documented deficiencies in reports of 
clinical trials. For example, information on the method 
used in a trial to assign participants to comparison groups 
was reported in only 21% of 519 trial reports indexed in 
PubMed in 2000,16 and only 34% of 616 reports indexed 
in 2006.17 Similarly, only 45% of trial reports indexed 
in PubMed in 200016 and 53% in 200617 defined a pri‑
mary end point, and only 27% in 2000 and 45% in 2006 
reported a sample size calculation. Reporting is not only 
often incomplete but also sometimes inaccurate. Of 119 
reports stating that all participants were included in 
the analysis in the groups to which they were originally 
assigned (intention‑to‑treat analysis), 15 (13%) excluded 
patients or did not analyse all patients as allocated.18 Many 
other reviews have found that inadequate reporting is com‑
mon in specialty journals16 19 and journals published in 
languages other than English.20 21
Proper randomisation reduces selection bias at trial 
entry and is the crucial component of high quality RCTs.22 
Successful randomisation hinges on two steps: generation 
of an unpredictable allocation sequence and concealment 
of this sequence from the investigators enrolling partici‑
pants (see box 1).2 23
Unfortunately, despite that central role, reporting of 
the methods used for allocation of participants to inter‑
ventions is also generally inadequate. For example, 5% 
of 206 reports of supposed RCTs in obstetrics and gynae‑
cology journals described studies that were not truly ran‑
domised.23 This estimate is conservative, as most reports 
do not at present provide adequate information about the 
method of allocation.20 23 30‑ 33
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abstract
Overwhelming evidence shows the quality of reporting of randomised controlled trials (RCTs) is not optimal. Without 
transparent reporting, readers cannot judge the reliability and validity of trial findings nor extract information for systematic 
reviews. Recent methodological analyses indicate that inadequate reporting and design are associated with biased estimates 
of treatment effects. Such systematic error is seriously damaging to RCTs, which are considered the gold standard for 
evaluating interventions because of their ability to minimise or avoid bias.
A group of scientists and editors developed the CONSORT (Consolidated Standards of Reporting Trials) statement to improve 
the quality of reporting of RCTs. It was first published in 1996 and updated in 2001. The statement consists of a checklist 
and flow diagram that authors can use for reporting an RCT. Many leading medical journals and major international editorial 
groups have endorsed the CONSORT statement. The statement facilitates critical appraisal and interpretation of RCTs.
During the 2001 CONSORT revision, it became clear that explanation and elaboration of the principles underlying the 
CONSORT statement would help investigators and others to write or appraise trial reports. A CONSORT explanation and 
elaboration article was published in 2001 alongside the 2001 version of the CONSORT statement.
After an expert meeting in January 2007, the CONSORT statement has been further revised and is published as the CONSORT 
2010 Statement. This update improves the wording and clarity of the previous checklist and incorporates recommendations 
related to topics that have only recently received recognition, such as selective outcome reporting bias.
This explanatory and elaboration document—intended to enhance the use, understanding, and dissemination of the 
CONSORT statement—has also been extensively revised. It presents the meaning and rationale for each new and updated 
checklist item providing examples of good reporting and, where possible, references to relevant empirical studies. Several 
examples of flow diagrams are included.
The CONSORT 2010 Statement, this revised explanatory and elaboration document, and the associated website (www.
consort-statement.org) should be helpful resources to improve reporting of randomised trials.
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improving the reporting of rcts: the consort statement
DerSimonian and colleagues suggested that “editors could 
greatly improve the reporting of clinical trials by providing 
authors with a list of items that they expected to be strictly 
reported.”34 Early in the 1990s, two groups of journal edi‑
tors, trialists, and methodologists independently published 
recommendations on the reporting of trials.35 36 In a subse‑
quent editorial, Rennie urged the two groups to meet and 
develop a common set of recommendations 37; the outcome 
was the CONSORT statement (Consolidated Standards of 
Reporting Trials).38
The CONSORT statement (or simply CONSORT) comprises 
a checklist of essential items that should be included in 
reports of RCTs and a diagram for documenting the flow of 
participants through a trial. It is aimed at primary reports of 
RCTs with two group, parallel designs. Most of CONSORT is 
also relevant to a wider class of trial designs, such as non‑
inferiority, equivalence, factorial, cluster, and crossover tri‑
als. Extensions to the CONSORT checklist for reporting trials 
with some of these designs have been published,39‑41 as have 
those for reporting certain types of data (harms 42), types of 
interventions (non‑pharmacological treatments 43, herbal 
interventions44), and abstracts.45
The objective of CONSORT is to provide guidance to authors 
about how to improve the reporting of their trials. Trial reports 
need be clear, complete, and transparent. Readers, peer 
reviewers, and editors can also use CONSORT to help them 
critically appraise and interpret reports of RCTs. However, 
CONSORT was not meant to be used as a quality assessment 
instrument. Rather, the content of CONSORT focuses on items 
related to the internal and external validity of trials. Many 
items not explicitly mentioned in CONSORT should also be 
included in a report, such as information about approval by 
an ethics committee, obtaining informed consent from par‑
ticipants, and, where relevant, existence of a data safety and 
monitoring committee. In addition, any other aspects of a 
trial that are mentioned should be properly reported, such 
as information pertinent to cost effectiveness analysis.46‑48
Since its publication in 1996, CONSORT has been sup‑
ported by more than 400 journals (www.consort‑statement.
org) and several editorial groups, such as the International 
Committee of Medical Journal Editors.49 The introduction 
of CONSORT within journals is associated with improved 
quality of reports of RCTs.17 50 51 However, CONSORT is an 
ongoing initiative, and the CONSORT statement is revised 
periodically.3 CONSORT was last revised nine years ago, in 
2001.52‑54 Since then the evidence base to inform CONSORT 
has grown considerably; empirical data have highlighted new 
concerns regarding the reporting of RCTs, such as selective 
outcome reporting.55‑57 A CONSORT Group meeting was there‑
fore convened in January 2007, in Canada, to revise the 2001 
CONSORT statement and its accompanying explanation and 
elaboration document. The revised checklist is shown in table 
1 and the flow diagram, not revised, in fig 1.52‑54
the consort 2010 statement: explanation and 
elaboration
During the 2001 CONSORT revision, it became clear that 
explanation and elaboration of the principles underlying 
the CONSORT statement would help investigators and others 
to write or appraise trial reports. The CONSORT explanation 
and elaboration article58 was published in 2001 alongside 
the 2001 version of the CONSORT statement. It discussed the 
rationale and scientific background for each item and pro‑
vided published examples of good reporting. The rationale 
for revising that article is similar to that for revising the state‑
ment, described above. We briefly describe below the main 
additions and deletions to this version of the explanation and 
elaboration article.
the consort 2010 explanation and elaboration: changes
We have made several substantive and some cosmetic 
changes to this version of the CONSORT explanatory docu‑
ment (full details are highlighted in the 2010 version of the 
CONSORT statement59). Some reflect changes to the CON‑
box 1 |  Treatment allocation. What’s so special about randomisation?
The method used to assign interventions to trial participants is a crucial aspect of clinical trial design. Random assignment is the preferred method; it has been 
successfully used regularly in trials for more than 50 years.24 Randomisation has three major advantages.25 First, when properly implemented, it eliminates 
selection bias, balancing both known and unknown prognostic factors, in the assignment of treatments. Without randomisation, treatment comparisons 
may be prejudiced, whether consciously or not, by selection of participants of a particular kind to receive a particular treatment. Second, random assignment 
permits the use of probability theory to express the likelihood that any difference in outcome between intervention groups merely reflects chance.26 Third, 
random allocation, in some situations, facilitates blinding the identity of treatments to the investigators, participants, and evaluators, possibly by use of a 
placebo, which reduces bias after assignment of treatments.27 Of these three advantages, reducing selection bias at trial entry is usually the most important.28
Successful randomisation in practice depends on two interrelated aspects—adequate generation of an unpredictable allocation sequence and concealment 
of that sequence until assignment occurs.2 23 A key issue is whether the schedule is known or predictable by the people involved in allocating participants to 
the comparison groups.29 The treatment allocation system should thus be set up so that the person enrolling participants does not know in advance which 
treatment the next person will get, a process termed allocation concealment.2 23 Proper allocation concealment shields knowledge of forthcoming assignments, 
whereas proper random sequences prevent correct anticipation of future assignments based on knowledge of past assignments.
Fig 1 | Flow diagram of the progress through the phases of a parallel randomised trial of two 
groups (that is, enrolment, intervention allocation, follow-up, and data analysis)52-54
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Assessed for eligibility (n=...)
Randomised (n=...)
Lost to follow-up (give reasons) (n=...)
Discontinued intervention (give reasons) (n=...)
Lost to follow-up (give reasons) (n=...)
Discontinued intervention (give reasons) (n=...)
Analysed (n=...):
  Excluded from analysis (give reasons) (n=...)
Analysed (n=...):
  Excluded from analysis (give reasons) (n=...)
Excluded (n=...):
  Not meeting inclusion criteria (n=...)
  Declined to participate (n=...)
  Other reasons (n=...)
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SORT  checklist; there are three new checklist items in the 
CONSORT 2010 checklist—such as item 24, which asks 
authors to report where their trial protocol can be accessed. 
We have also updated some existing explanations, including 
adding more recent references to methodological evidence, 
and used some better examples. We have removed the glos‑
sary, which is now  available on the CONSORT website (www.
consort‑statement.org). Where possible, we describe the 
findings of relevant empirical studies. Many excellent books 
on clinical trials offer fuller discussion of methodological 
issues.60‑62 Finally, for convenience, we sometimes refer to 
“treatments” and “patients,” although we recognise that not 
all interventions evaluated in RCTs are treatments and not 
all participants are patients.
table 1 | CONSORT 2010 checklist of information to include when reporting a randomised trial*
Section/Topic Item No Checklist item Reported on page No
Title and abstract
1a Identification as a randomised trial in the title
1b Structured summary of trial design, methods, results, and conclusions (for specific guidance see CONSORT for 
abstracts45 65)
Introduction
Background and objectives 2a Scientific background and explanation of rationale
2b Specific objectives or hypotheses
Methods
Trial design 3a Description of trial design (such as parallel, factorial) including allocation ratio
3b Important changes to methods after trial commencement (such as eligibility criteria), with reasons
Participants 4a Eligibility criteria for participants
4b Settings and locations where the data were collected
Interventions 5 The interventions for each group with sufficient details to allow replication, including how and when they were actually 
administered
Outcomes 6a Completely defined pre-specified primary and secondary outcome measures, including how and when they were 
assessed
6b Any changes to trial outcomes after the trial commenced, with reasons
Sample size 7a How sample size was determined
7b When applicable, explanation of any interim analyses and stopping guidelines
Randomisation:
 Sequence generation 8a Method used to generate the random allocation sequence
8b Type of randomisation; details of any restriction (such as blocking and block size)
 Allocation concealment 
mechanism
9 Mechanism used to implement the random allocation sequence (such as sequentially numbered containers), 
describing any steps taken to conceal the sequence until interventions were assigned
 Implementation 10 Who generated the random allocation sequence, who enrolled participants, and who assigned participants to 
interventions
Blinding 11a If done, who was blinded after assignment to interventions (for example, participants, care providers, those assessing 
outcomes) and how
11b If relevant, description of the similarity of interventions
Statistical methods 12a Statistical methods used to compare groups for primary and secondary outcomes
12b Methods for additional analyses, such as subgroup analyses and adjusted analyses
Results
Participant flow (a diagram is 
strongly recommended)
13a For each group, the numbers of participants who were randomly assigned, received intended treatment, and were 
analysed for the primary outcome
13b For each group, losses and exclusions after randomisation, together with reasons
Recruitment 14a Dates defining the periods of recruitment and follow-up
14b Why the trial ended or was stopped
Baseline data 15 A table showing baseline demographic and clinical characteristics for each group
Numbers analysed 16 For each group, number of participants (denominator) included in each analysis and whether the analysis was by 
original assigned groups
Outcomes and estimation 17a For each primary and secondary outcome, results for each group, and the estimated effect size and its precision (such 
as 95% confidence interval)
17b For binary outcomes, presentation of both absolute and relative effect sizes is recommended
Ancillary analyses 18 Results of any other analyses performed, including subgroup analyses and adjusted analyses, distinguishing pre-
specified from exploratory
Harms 19 All important harms or unintended effects in each group (for specific guidance see CONSORT for harms42)
Discussion
Limitations 20 Trial limitations, addressing sources of potential bias, imprecision, and, if relevant, multiplicity of analyses
Generalisability 21 Generalisability (external validity, applicability) of the trial findings
Interpretation 22 Interpretation consistent with results, balancing benefits and harms, and considering other relevant evidence
Other information
Registration 23 Registration number and name of trial registry
Protocol 24 Where the full trial protocol can be accessed, if available
Funding 25 Sources of funding and other support (such as supply of drugs), role of funders
*We strongly recommend reading this statement in conjunction with the CONSORT 2010 Explanation and Elaboration for important clarifications on all the items. If relevant, we also recommend 
reading CONSORT extensions for cluster randomised trials,40 non-inferiority and equivalence trials,39 non-pharmacological treatments,43 herbal interventions,44 and pragmatic trials.41 Additional 
extensions are forthcoming: for those and for up to date references relevant to this checklist, see www.consort-statement.org.
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of the full article.68‑71 Conversely, omitting important harms 
from the abstract could seriously mislead someone’s inter‑
pretation of the trial findings.42 72
A recent extension to the CONSORT statement provides 
a list of essential items that authors should include when 
reporting the main results of a randomised trial in a jour‑
nal (or conference) abstract (see table 2).45 We strongly 
recommend the use of structured abstracts for reporting ran‑
domised trials. They provide readers with information about 
the trial under a series of headings pertaining to the design, 
conduct, analysis, and interpretation.73 Some studies have 
found that structured abstracts are of higher quality than the 
more traditional descriptive abstracts74 75 and that they allow 
readers to find information more easily.76 We recognise that 
many journals have developed their own structure and word 
limit for reporting abstracts. It is not our intention to suggest 
changes to these formats, but to recommend what informa‑
tion should be reported.
introduction
Item 2a. Scientific background and explanation of rationale
Example—“Surgery is the treatment of choice for patients 
with disease stage I and II non‑small cell lung cancer (NSCLC) 
… An NSCLC meta‑analysis combined the results from eight 
randomised trials of surgery versus surgery plus adjuvant 
cisplatin‑based chemotherapy and showed a small, but not 
significant (p=0.08), absolute survival benefit of around 5% 
at 5 years (from 50% to 55%). At the time the current trial 
was designed (mid‑1990s), adjuvant chemotherapy had not 
become standard clinical practice … The clinical rationale 
for neo‑adjuvant chemotherapy is three‑fold: regression of 
the primary cancer could be achieved thereby facilitating 
and simplifying or reducing subsequent surgery; undetected 
 micro‑metastases could be dealt with at the start of treat‑
ment; and there might be inhibition of the putative stimu‑
lus to residual cancer by growth factors released by surgery 
and by subsequent wound healing … The current trial was 
therefore set up to compare, in patients with resectable 
NSCLC, surgery alone versus three cycles of platinum‑based 
chemotherapy followed by surgery in terms of overall sur‑
vival, quality of life, pathological staging, resectability rates, 
extent of surgery, and time to and site of relapse.”77
Explanation—Typically, the introduction consists of free 
flowing text, in which authors explain the scientific back‑
ground and rationale for their trial, and its general outline. 
It may also be appropriate to include here the objectives of 
the trial (see item 2b).The rationale may be explanatory 
(for example, to assess the possible influence of a drug on 
renal function) or pragmatic (for example, to guide practice 
by comparing the benefits and harms of two treatments). 
Authors should report any evidence of the benefits and 
harms of active interventions included in a trial and should 
suggest a plausible explanation for how the interventions 
might work, if this is not obvious.78
The Declaration of Helsinki states that biomedical 
research involving people should be based on a thorough 
knowledge of the scientific literature.79 That is, it is unethi‑
cal to expose humans unnecessarily to the risks of research. 
Some clinical trials have been shown to have been unneces‑
sary because the question they addressed had been or could 
have been answered by a systematic review of the existing 
checklist items
Title and abstract
Item 1a. Identification as a randomised trial in the title.
Example—“Smoking reduction with oral nicotine inhal‑
ers: double blind, randomised clinical trial of efficacy and 
safety.”63
Explanation—The ability to identify a report of a randomised 
trial in an electronic database depends to a large extent on 
how it was indexed. Indexers may not classify a report as a 
randomised trial if the authors do not explicitly report this 
information.64 To help ensure that a study is appropriately 
indexed and easily identified, authors should use the word 
“randomised” in the title to indicate that the participants 
were randomly assigned to their comparison groups.
Item 1b. Structured summary of trial design, methods, results, and 
conclusions
For specific guidance see CONSORT for abstracts.45 65
Explanation—Clear, transparent, and sufficiently detailed 
abstracts are important because readers often base their 
assessment of a trial on such information. Some readers 
use an abstract as a screening tool to decide whether to 
read the full article. However, as not all trials are freely 
available and some health professionals do not have access 
to the full trial reports, healthcare decisions are sometimes 
made on the basis of abstracts of randomised trials.66
A journal abstract should contain sufficient information 
about a trial to serve as an accurate record of its conduct 
and findings, providing optimal information about the 
trial within the space constraints and format of a journal. A 
properly constructed and written abstract helps individuals 
to assess quickly the relevance of the findings and aids the 
retrieval of relevant reports from electronic databases.67 The 
abstract should accurately reflect what is included in the full 
journal article and should not include information that does 
not appear in the body of the paper. Studies comparing the 
accuracy of information reported in a journal abstract with 
that reported in the text of the full publication have found 
claims that are inconsistent with, or missing from, the body 
table 2 | Items to include when reporting a randomised trial in a journal abstract 
Item Description
Authors Contact details for the corresponding author
Trial design Description of the trial design (such as parallel, cluster, non-inferiority)
Methods:
 Participants Eligibility criteria for participants and the settings where the data were collected
 Interventions Interventions intended for each group
 Objective Specific objective or hypothesis
 Outcome Clearly defined primary outcome for this report
 Randomisation How participants were allocated to interventions
 Blinding (masking) Whether participants, care givers, and those assessing the outcomes were blinded to 
group assignment
Results:
 Numbers 
randomised
Number of participants randomised to each group
 Recruitment Trial status
 Numbers analysed Number of participants analysed in each group
 Outcome For the primary outcome, a result for each group and the estimated effect size and its 
precision
 Harms Important adverse events or side effects
Conclusions General interpretation of the results
Trial registration Registration number and name of trial register
Funding Source of funding
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either one of five otamixaban … regimens … or an active 
control of unfractionated heparin … an independent Data 
Monitoring Committee reviewed unblinded data for patient 
safety; no interim analyses for efficacy or futility were 
done. During the trial, this committee recommended that 
the group receiving the lowest dose of otamixaban (0·035 
mg/kg/h) be discontinued because of clinical evidence of 
inadequate anticoagulation. The protocol was immediately 
amended in accordance with that recommendation, and 
participants were subsequently randomly assigned in 
2:2:2:2:1 ratio to the remaining otamixaban and control 
groups, respectively.”86
Explanation—A few trials may start without any fixed plan 
(that is, are entirely exploratory), but the most will have a 
protocol that specifies in great detail how the trial will be 
conducted. There may be deviations from the original pro‑
tocol, as it is impossible to predict every possible change 
in circumstances during the course of a trial. Some trials 
will therefore have important changes to the methods after 
trial commencement.
Changes could be due to external information becoming 
available from other studies, or internal financial difficul‑
ties, or could be due to a disappointing recruitment rate. 
Such protocol changes should be made without breaking 
the blinding on the accumulating data on participants’ 
outcomes. In some trials, an independent data monitoring 
committee will have as part of its remit the possibility of rec‑
ommending protocol changes based on seeing unblinded 
data. Such changes might affect the study methods (such 
as changes to treatment regimens, eligibility criteria, ran‑
domisation ratio, or duration of follow‑up) or trial conduct 
(such as dropping a centre with poor data quality).87
Some trials are set up with a formal “adaptive” design. 
There is no universally accepted definition of these designs, 
but a working definition might be “a multistage study 
design that uses accumulating data to decide how to mod‑
ify aspects of the study without undermining the validity 
and integrity of the trial.”88 The modifications are usually 
to the sample sizes and the number of treatment arms and 
can lead to decisions being made more quickly and with 
more efficient use of resources. There are, however, impor‑
tant ethical, statistical, and practical issues in considering 
such a design.89 90
Whether the modifications are explicitly part of the 
trial design or in response to changing circumstances, it 
is essential that they are fully reported to help the reader 
interpret the results. Changes from protocols are not cur‑
rently well reported. A review of comparisons with proto‑
cols showed that about half of journal articles describing 
RCTs had an unexplained discrepancy in the primary out‑
comes.57 Frequent unexplained discrepancies have also 
been observed for details of randomisation, blinding,91 
and statistical analyses.92
Item 4a. Eligibility criteria for participants
Example—“Eligible participants were all adults aged 18 or 
over with HIV who met the eligibility criteria for antiretroviral 
therapy according to the Malawian national HIV treatment 
guidelines (WHO clinical stage III or IV or any WHO stage 
with a CD4 count <250/mm3) and who were starting treat‑
ment with a BMI <18.5. Exclusion criteria were pregnancy 
literature.80 81 Thus, the need for a new trial should be justi‑
fied in the introduction. Ideally, it should include a reference 
to a systematic review of previous similar trials or a note of 
the absence of such trials.82
Item 2b. Specific objectives or hypotheses
Example—“In the current study we tested the hypothesis 
that a policy of active management of nulliparous labour 
would: 1. reduce the rate of caesarean section, 2. reduce 
the rate of prolonged labour; 3. not influence maternal 
 satisfaction with the birth experience.”83
Explanation—Objectives are the questions that the trial 
was designed to answer. They often relate to the efficacy of 
a particular therapeutic or preventive intervention. Hypoth‑
eses are pre‑specified questions being tested to help meet 
the objectives. Hypotheses are more specific than  objectives 
and are amenable to explicit statistical evaluation. In 
practice, objectives and hypotheses are not always easily 
 differentiated. Most reports of RCTs provide adequate infor‑
mation about trial objectives and hypotheses.84
Methods
Item 3a. Description of trial design (such as parallel, factorial) 
including allocation ratio
Example—“This was a multicenter, stratified (6 to 11 years 
and 12 to 17 years of age, with imbalanced randomisation 
[2:1]), double‑blind, placebo‑controlled, parallel‑group 
study conducted in the United States (41 sites).”85
Explanation—The word “design” is often used to refer to 
all aspects of how a trial is set up, but it also has a narrower 
interpretation. Many specific aspects of the broader trial 
design, including details of randomisation and blinding, 
are addressed elsewhere in the CONSORT checklist. Here 
we seek information on the type of trial, such as parallel 
group or factorial, and the conceptual framework, such as 
superiority or non‑inferiority, and other related issues not 
addressed elsewhere in the checklist.
The CONSORT statement focuses mainly on trials with par‑
ticipants individually randomised to one of two “parallel” 
groups. In fact, little more than half of published trials have 
such a design.16 The main alternative designs are multi‑arm 
parallel, crossover, cluster,40 and factorial designs. Also, most 
trials are set to identify the superiority of a new intervention, 
if it exists, but others are designed to assess non‑inferiority or 
equivalence.39 It is important that researchers clearly describe 
these aspects of their trial, including the unit of randomisa‑
tion (such as patient, GP practice, lesion). It is desirable also 
to include these details in the abstract (see item 1b).
If a less common design is employed, authors are encour‑
aged to explain their choice, especially as such designs may 
imply the need for a larger sample size or more complex 
analysis and interpretation.
Although most trials use equal randomisation (such as 
1:1 for two groups), it is helpful to provide the allocation 
ratio explicitly. For drug trials, specifying the phase of the 
trial (I‑IV) may also be relevant.
Item 3b. Important changes to methods after trial commencement 
(such as eligibility criteria), with reasons
Example—“Patients were randomly assigned to one of 
six parallel groups, initially in 1:1:1:1:1:1 ratio, to receive 
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and lactation or participation in another supplementary feed‑
ing programme.”93
Explanation—A comprehensive description of the eligibility 
criteria used to select the trial participants is needed to help 
readers interpret the study. In particular, a clear understand‑
ing of these criteria is one of several elements required to 
judge to whom the results of a trial apply—that is, the trial’s 
generalisability (applicability) and relevance to clinical or 
public health practice (see item 21).94 A description of the 
method of recruitment, such as by referral or self selection 
(for example, through advertisements), is also important in 
this context. Because they are applied before randomisation, 
eligibility criteria do not affect the internal validity of a trial, 
but they are central to its external validity.
Typical and widely accepted selection criteria relate to the 
nature and stage of the disease being studied, the exclusion 
of persons thought to be particularly vulnerable to harm from 
the study intervention, and to issues required to ensure that 
the study satisfies legal and ethical norms. Informed consent 
by study participants, for example, is typically required in 
intervention studies. The common distinction between inclu‑
sion and exclusion criteria is unnecessary; the same criterion 
can be phrased to include or exclude participants.95
Despite their importance, eligibility criteria are often not 
reported adequately. For example, eight published trials 
leading to clinical alerts by the National Institutes of Health 
specified an average of 31 eligibility criteria in their pro‑
tocols, but only 63% of the criteria were mentioned in the 
journal articles, and only 19% were mentioned in the clini‑
cal alerts.96 Similar deficiencies were found for HIV clinical 
trials.97 Among 364 reports of RCTs in surgery, 25% did not 
specify any eligibility criteria.98
Item 4b. Settings and locations where the data were collected
Example—“The study took place at the antiretroviral therapy 
clinic of Queen Elizabeth Central Hospital in Blantyre, Malawi, 
from January 2006 to April 2007. Blantyre is the major com‑
mercial city of Malawi, with a population of 1 000 000 and an 
estimated HIV prevalence of 27% in adults in 2004.”93
Explanation—Along with the eligibility criteria for partici‑
pants (see item 4a) and the description of the interventions 
(see item 5), information on the settings and locations is 
crucial to judge the applicability and generalisability of a 
trial. Were participants recruited from primary, secondary, 
or tertiary health care or from the community? Healthcare 
institutions vary greatly in their organisation, experience, and 
resources and the baseline risk for the condition under inves‑
tigation. Other aspects of the setting (including the social, 
economic, and cultural environment and the climate) may 
also affect a study’s external validity.
Authors should report the number and type of settings and 
describe the care providers involved. They should report the 
locations in which the study was carried out, including the 
country, city if applicable, and immediate environment (for 
example, community, office practice, hospital clinic, or inpa‑
tient unit). In particular, it should be clear whether the trial 
was carried out in one or several centres (“multicentre trials”). 
This description should provide enough information so that 
readers can judge whether the results of the trial could be 
relevant to their own setting. The environment in which the 
trial is conducted may differ considerably from the setting in 
which the trial’s results are later used to guide practice and 
policy.94 99 Authors should also report any other information 
about the settings and locations that could have influenced 
the observed results, such as problems with transportation 
that might have affected patient participation or delays in 
administering interventions.
Item 5. The interventions for each group with sufficient details to 
allow replication, including how and when they were actually 
administered
Examples—“In POISE, patients received the first dose of the 
study drug (ie, oral extended‑release metoprolol 100 mg or 
matching placebo) 2‑4 h before surgery. Study drug adminis‑
tration required a heart rate of 50 bpm or more and a systolic 
blood pressure of 100 mm Hg or greater; these haemodynam‑
ics were checked before each administration. If, at any time 
during the first 6 h after surgery, heart rate was 80 bpm or 
more and systolic blood pressure was 100 mm Hg or higher, 
patients received their first postoperative dose (extended‑
release metoprolol 100 mg or matched placebo) orally. If 
the study drug was not given during the first 6 h, patients 
received their first postoperative dose at 6 h after surgery. 12 
h after the first postoperative dose, patients started taking oral 
extended‑release metoprolol 200 mg or placebo every day for 
30 days. If a patient’s heart rate was consistently below 45 
bpm or their systolic blood pressure dropped below 100 mm 
Hg, study drug was withheld until their heart rate or systolic 
blood pressure recovered; the study drug was then restarted 
at 100 mg once daily. Patients whose heart rate was consist‑
ently 45‑49 bpm and systolic blood pressure exceeded 100 
mm Hg delayed taking the study drug for 12 h.”100
“Patients were randomly assigned to receive a custom‑
made neoprene splint to be worn at night or to usual care. 
The splint was a rigid rest orthosis recommended for use only 
at night. It covered the base of the thumb and the thenar emi‑
nence but not the wrist (Figure 1). Splints were made by 3 
trained occupational therapists, who adjusted the splint for 
each patient so that the first web could be opened and the 
thumb placed in opposition with the first long finger. Patients 
were encouraged to contact the occupational therapist if 
they felt that the splint needed adjustment, pain increased 
while wearing the splint, or they had adverse effects (such as 
skin erosion). Because no treatment can be considered the 
gold standard in this situation, patients in the control and 
intervention groups received usual care at the discretion of 
their physician (general practitioner or rheumatologist). We 
decided not to use a placebo because, to our knowledge, no 
placebo for splinting has achieved successful blinding of 
patients, as recommended.”101
Explanation—Authors should describe each intervention 
thoroughly, including control interventions. The description 
should allow a clinician wanting to use the intervention to 
know exactly how to administer the intervention that was 
evaluated in the trial.102 For a drug intervention, informa‑
tion would include the drug name, dose, method of admin‑
istration (such as oral, intravenous), timing and duration of 
administration, conditions under which interventions are 
withheld, and titration regimen if applicable. If the control 
group is to receive “usual care” it is important to describe 
thoroughly what that constitutes. If the control group or 
intervention group is to receive a combination of interven‑
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macological trials, a third of the claims of treatment supe‑
riority based on unpublished scales would not have been 
made if a published scale had been used.109 Similar data 
have been reported elsewhere.110 111 Only 45% of a cohort 
of 519 RCTs published in 2000 specified the primary out‑
come16; this compares with 53% for a similar cohort of 614 
RCTs published in 2006.17
Item 6b. Any changes to trial outcomes after the trial commenced, 
with reasons
Example—“The original primary endpoint was all‑cause 
mortality, but, during a masked analysis, the data and 
safety monitoring board noted that overall mortality was 
lower than had been predicted and that the study could 
not be completed with the sample size and power origi‑
nally planned. The steering committee therefore decided 
to adopt co‑primary endpoints of all‑cause mortality (the 
original primary endpoint), together with all‑cause mor‑
tality or cardiovascular hospital admissions (the first pre‑
specified secondary endpoint).”112
Explanation—There are many reasons for departures 
from the initial study protocol (see item 24). Authors 
should report all major changes to the protocol, including 
unplanned changes to eligibility criteria, interventions, 
examinations, data collection, methods of analysis, and 
outcomes. Such information is not always reported.
As indicated earlier (see item 6a), most trials record mul‑
tiple outcomes, with the risk that results will be reported for 
only a selected subset (see item 17). Pre‑specification and 
reporting of primary and secondary outcomes (see item 
6a) should remove such a risk. In some trials, however, 
circumstances require a change in the way an outcome is 
assessed or even, as in the example above, a switch to a 
different outcome. For example, there may be external evi‑
dence from other trials or systematic reviews suggesting the 
end point might not be appropriate, or recruitment or the 
overall event rate in the trial may be lower than expected.112 
Changing an end point based on unblinded data is much 
more problematic, although it may be specified in the con‑
text of an adaptive trial design.88 Authors should identify 
and explain any such changes. Likewise, any changes after 
the trial began of the designation of outcomes as primary 
or secondary should be reported and explained.
A comparison of protocols and publications of 102 
randomised trials found that 62% of trials reports had at 
least one primary outcome that was changed, introduced, 
or omitted compared with the protocol.55 Primary outcomes 
also differed between protocols and publications for 40% 
of a cohort of 48 trials funded by the Canadian Institutes 
of Health Research.113 Not one of the subsequent 150 trial 
reports mentioned, let alone explained, changes from 
the protocol. Similar results from other studies have been 
reported recently in a systematic review of empirical stud‑
ies examining outcome reporting bias.57
Item 7a. How sample size was determined
Examples—“To detect a reduction in PHS (postoperative 
hospital stay) of 3 days (SD 5 days), which is in agree‑
ment with the study of Lobo et al17 with a two‑sided 5% 
significance level and a power of 80%, a sample size of 
50 patients per group was necessary, given an anticipated 
tions the authors should provide a thorough description of 
each intervention, an explanation of the order in which the 
combination of interventions are introduced or withdrawn, 
and the triggers for their introduction if applicable.
Specific extensions of the CONSORT statement address the 
reporting of non‑pharmacologic and herbal interventions and 
their particular reporting requirements (such as expertise, 
details of how the interventions were standardised).43 44 We 
recommend readers consult the statements for non‑pharma‑
cologic and herbal interventions as appropriate.
Item 6a. Completely defined pre-specified primary and secondary 
outcome measures, including how and when they were assessed
Example—“The primary endpoint with respect to efficacy 
in psoriasis was the proportion of patients achieving a 75% 
improvement in psoriasis activity from baseline to 12 weeks 
as measured by the PASI [psoriasis area and severity index] 
Additional analyses were done on the percentage change in 
PASI scores and improvement in target psoriasis lesions.”103
Explanation—All RCTs assess response variables, or out‑
comes (end points), for which the groups are compared. 
Most trials have several outcomes, some of which are of 
more interest than others. The primary outcome measure 
is the pre‑specified outcome considered to be of greatest 
importance to relevant stakeholders (such a patients, pol‑
icy makers, clinicians, funders) and is usually the one used 
in the sample size calculation (see item 7). Some trials may 
have more than one primary outcome. Having several pri‑
mary outcomes, however, incurs the problems of interpre‑
tation associated with multiplicity of analyses (see items 
18 and 20) and is not recommended. Primary outcomes 
should be explicitly indicated as such in the report of an 
RCT. Other outcomes of interest are secondary outcomes 
(additional outcomes). There may be several secondary 
outcomes, which often include unanticipated or unin‑
tended effects of the intervention (see item 19), although 
harms should always be viewed as important whether they 
are labelled primary or secondary.
All outcome measures, whether primary or secondary, 
should be identified and completely defined. The principle 
here is that the information provided should be sufficient to 
allow others to use the same outcomes.102 When outcomes 
are assessed at several time points after randomisation, 
authors should also indicate the pre‑specified time point 
of primary interest. For many non‑pharmacological inter‑
ventions it is helpful to specify who assessed outcomes (for 
example, if special skills are required to do so) and how 
many assessors there were.43
Where available and appropriate, the use of previously 
developed and validated scales or consensus guidelines 
should be reported,104 105 both to enhance quality of meas‑
urement and to assist in comparison with similar stud‑
ies.106 For example, assessment of quality of life is likely to 
be improved by using a validated instrument.107 Authors 
should indicate the provenance and properties of scales.
More than 70 outcomes were used in 196 RCTs of non‑
steroidal anti‑inflammatory drugs for rheumatoid arthri‑
tis,108 and 640 different instruments had been used in 2000 
trials in schizophrenia, of which 369 had been used only 
once.33 Investigation of 149 of those 2000 trials showed 
that unpublished scales were a source of bias. In non‑phar‑
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should individually have “sufficient power.” This debate will 
continue, and members of the CONSORT Group have vary‑
ing views. Critically however, the debate and those views are 
immaterial to reporting a trial. Whatever the power of a trial, 
authors need to properly report their intended size with all 
their methods and assumptions.118 That transparently reveals 
the power of the trial to readers and gives them a measure by 
which to assess whether the trial attained its planned size.
In some trials, interim analyses are used to help decide 
whether to stop early or to continue recruiting sometimes 
beyond the planned trial end (see item 7b). If the actual 
sample size differed from the originally intended sample 
size for some other reason (for example, because of poor 
recruitment or revision of the target sample size), the expla‑
nation should be given.
Reports of studies with small samples frequently include 
the erroneous conclusion that the intervention groups do 
not differ, when in fact too few patients were studied to 
make such a claim.120 Reviews of published trials have 
consistently found that a high proportion of trials have 
low power to detect clinically meaningful treatment 
effects.121‑123 In reality, small but clinically meaningful true 
differences are much more likely than large differences to 
exist, but large trials are required to detect them.124
In general, the reported sample sizes in trials seem 
small. The median sample size was 54 patients in 196 tri‑
als in arthritis,108 46 patients in 73 trials in dermatology,8 
and 65 patients in 2000 trials in schizophrenia.33 These 
small sample sizes are consistent with those of a study of 
519 trials indexed in PubMed in December 200016 and 
a similar cohort of trials (n=616) indexed in PubMed in 
2006,17 where the median number of patients recruited for 
parallel group trials was 80 across both years. Moreover, 
many reviews have found that few authors report how they 
determined the sample size.8 14 32 33 123
There is little merit in a post hoc calculation of statistical 
power using the results of a trial; the power is then appropri‑
ately indicated by confidence intervals (see item 17).125
Item 7b. When applicable, explanation of any interim analyses 
and stopping guidelines
Examples—“Two interim analyses were performed during 
the trial. The levels of significance maintained an overall P 
value of 0.05 and were calculated according to the O’Brien‑
Fleming stopping boundaries. This final analysis used a Z 
score of 1.985 with an associated P value of 0.0471.”126
“An independent data and safety monitoring board peri‑
odically reviewed the efficacy and safety data. Stopping 
rules were based on modified Haybittle‑Peto boundaries of 
4 SD in the first half of the study and 3 SD in the second half 
for efficacy data, and 3 SD in the first half of the study and 
2 SD in the second half for safety data. Two formal interim 
analyses of efficacy were performed when 50% and 75% 
of the expected number of primary events had accrued; no 
correction of the reported P value for these interim tests 
was performed.”127
Explanation—Many trials recruit participants over a long 
period. If an intervention is working particularly well or badly, 
the study may need to be ended early for ethical reasons. This 
concern can be addressed by examining results as the data 
accumulate, preferably by an independent data monitoring 
dropout rate of 10%. To recruit this number of patients a 
12‑month inclusion period was anticipated.”114
“Based on an expected incidence of the primary compos‑
ite endpoint of 11% at 2.25 years in the placebo group, we 
calculated that we would need 950 primary endpoint events 
and a sample size of 9650 patients to give 90% power to 
detect a significant difference between ivabradine and pla‑
cebo, corresponding to a 19% reduction of relative risk (with 
a two‑sided type 1 error of 5%). We initially designed an 
event‑driven trial, and planned to stop when 950 primary 
endpoint events had occurred. However, the incidence of 
the primary endpoint was higher than predicted, perhaps 
because of baseline characteristics of the recruited patients, 
who had higher risk than expected (e.g., lower proportion of 
NYHA class I and higher rates of diabetes and hypertension). 
We calculated that when 950 primary endpoint events had 
occurred, the most recently included patients would only 
have been treated for about 3 months. Therefore, in January 
2007, the executive committee decided to change the study 
from being event‑driven to time‑driven, and to continue the 
study until the patients who were randomised last had been 
followed up for 12 months. This change did not alter the 
planned study duration of 3 years.”115
Explanation—For scientific and ethical reasons, the sample 
size for a trial needs to be planned carefully, with a balance 
between medical and statistical considerations. Ideally, 
a study should be large enough to have a high probability 
(power) of detecting as statistically significant a clinically 
important difference of a given size if such a difference exists. 
The size of effect deemed important is inversely related to the 
sample size necessary to detect it; that is, large samples are 
necessary to detect small differences. Elements of the sam‑
ple size calculation are (1) the estimated outcomes in each 
group (which implies the clinically important target differ‑
ence between the intervention groups); (2) the α (type I) error 
level; (3) the statistical power (or the β (type II) error level); 
and (4), for continuous outcomes, the standard deviation of 
the measurements.116 The interplay of these elements and 
their reporting will differ for cluster trials40 and non‑inferior‑
ity and equivalence trials.39
Authors should indicate how the sample size was deter‑
mined. If a formal power calculation was used, the authors 
should identify the primary outcome on which the calcula‑
tion was based (see item 6a), all the quantities used in the 
calculation, and the resulting target sample size per study 
group. It is preferable to quote the expected result in the con‑
trol group and the difference between the groups one would 
not like to overlook. Alternatively, authors could present the 
percentage with the event or mean for each group used in 
their calculations. Details should be given of any allowance 
made for attrition or non‑compliance  during the study.
Some methodologists have written that so called under‑
powered trials may be acceptable because they could 
ultimately be combined in a systematic review and meta‑
analysis,117‑119 and because some information is better than 
no information. Of note, important caveats apply—such as 
the trial should be unbiased, reported properly, and pub‑
lished irrespective of the results, thereby becoming avail‑
able for meta‑analysis.118 On the other hand, many medical 
researchers worry that underpowered trials with indetermi‑
nate results will remain unpublished and insist that all trials 
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committee. However, performing multiple statistical exami‑
nations of accumulating data without appropriate correction 
can lead to erroneous results and interpretations.128 If the 
accumulating data from a trial are examined at five interim 
analyses that use a P value of 0.05, the overall false positive 
rate is nearer to 19% than to the nominal 5%.
Several group sequential statistical methods are avail‑
able to adjust for multiple analyses,129‑131 and their use 
should be pre‑specified in the trial protocol. With these 
methods, data are compared at each interim analysis, and 
a P value less than the critical value specified by the group 
sequential method indicates statistical significance. Some 
trialists use group sequential methods as an aid to deci‑
sion making,132 whereas others treat them as a formal stop‑
ping rule (with the intention that the trial will cease if the 
observed P value is smaller than the critical value).
Authors should report whether they or a data monitoring 
committee took multiple “looks” at the data and, if so, how 
many there were, what triggered them, the statistical meth‑
ods used (including any formal stopping rule), and whether 
they were planned before the start of the trial, before the 
data monitoring committee saw any interim data by alloca‑
tion, or some time thereafter. This information is often not 
included in published trial reports,133 even in trials that 
report stopping earlier than planned.134
Item 8a. Method used to generate the random allocation sequence
Examples—“Independent pharmacists dispensed either 
active or placebo inhalers according to a computer gener‑
ated randomisation list.”63
“For allocation of the participants, a computer‑generated 
list of random numbers was used.”135
Explanation—Participants should be assigned to com‑
parison groups in the trial on the basis of a chance (ran‑
dom) process characterised by unpredictability (see box 
1). Authors should provide sufficient information that the 
reader can assess the methods used to generate the random 
allocation sequence and the likelihood of bias in group 
assignment. It is important that information on the proc‑
ess of randomisation is included in the body of the main 
article and not as a separate supplementary file; where it 
can be missed by the reader.
The term “random” has a precise technical meaning. With 
random allocation, each participant has a known probabil‑
ity of receiving each intervention before one is assigned, but 
the assigned intervention is determined by a chance process 
and cannot be predicted. However, “random” is often used 
inappropriately in the literature to describe trials in which 
non‑random, deterministic allocation methods were used, 
such as alternation, hospital numbers, or date of birth. When 
investigators use such non‑random methods, they should 
describe them precisely and should not use the term “ran‑
dom” or any variation of it. Even the term “quasi‑random” 
is unacceptable for describing such trials. Trials based on 
non‑random methods generally yield biased results.2‑4 136 
Bias presumably arises from the inability to conceal these 
allocation systems adequately (see item 9).
Many methods of sequence generation are adequate. 
However, readers cannot judge adequacy from such terms as 
“random allocation,” “randomisation,” or “random” with‑
out further elaboration. Authors should specify the method 
of sequence generation, such as a random‑number table or a 
computerised random number generator. The sequence may 
be generated by the process of minimisation, a non‑random 
but generally acceptable method (see box 2).
In some trials, participants are intentionally allocated in 
unequal numbers to each intervention: for example, to gain 
more experience with a new procedure or to limit costs of 
the trial. In such cases, authors should report the randomi‑
sation ratio (for example, 2:1 or two treatment participants 
per each control participant) (see item 3a).
In a representative sample of PubMed indexed trials in 
2000, only 21% reported an adequate approach to random 
sequence generation16; this increased to 34% for a similar 
box 2 |  Randomisation and minimisation
•	Simple randomisation—Pure randomisation based on a single allocation ratio is known as simple randomisation. Simple randomisation with a 1:1 allocation 
ratio is analogous to a coin toss, although we do not advocate coin tossing for randomisation in an RCT. “Simple” is somewhat of a misnomer. While other 
randomisation schemes sound complex and more sophisticated, in reality, simple randomisation is elegantly sophisticated in that it is more unpredictable and 
surpasses the bias prevention levels of all other alternatives.
•	Restricted randomisation—Any randomised approach that is not simple randomisation. Blocked randomisation is the most common form. Other means of 
restricted randomisation include replacement, biased coin, and urn randomisation, although these are used much less frequently.141
•	Blocked randomisation—Blocking is used to ensure that comparison groups will be generated according to a predetermined ratio, usually 1:1 or groups of 
approximately the same size. Blocking can be used to ensure close balance of the numbers in each group at any time during the trial. For every block of eight 
participants, for example, four would be allocated to each arm of the trial.142 Improved balance comes at the cost of reducing the unpredictability of the sequence. 
Although the order of interventions varies randomly within each block, a person running the trial could deduce some of the next treatment allocations if he or she 
knew the block size.143 Blinding the interventions, using larger block sizes, and randomly varying the block size can ameliorate this problem.
•	Stratified randomisation—Stratification is used to ensure good balance of participant characteristics in each group. By chance, particularly in small trials, study 
groups may not be well matched for baseline characteristics, such as age and stage of disease. This weakens the trial’s credibility.144 Such imbalances can be 
avoided without sacrificing the advantages of randomisation. Stratification ensures that the numbers of participants receiving each intervention are closely 
balanced within each stratum. Stratified randomisation is achieved by performing a separate randomisation procedure within each of two or more subsets of 
participants (for example, those defining each study centre, age, or disease severity). Stratification by centre is common in multicentre trials. Stratification requires 
some form of restriction (such as blocking within strata). Stratification without blocking is ineffective.
•	Minimisation—Minimisation ensures balance between intervention groups for several selected patient factors (such as age).22 60 The first patient is truly randomly 
allocated; for each subsequent participant, the treatment allocation that minimises the imbalance on the selected factors between groups at that time is identified. 
That allocation may then be used, or a choice may be made at random with a heavy weighting in favour of the intervention that would minimise imbalance (for 
example, with a probability of 0.8). The use of a random component is generally preferable. Minimisation has the advantage of making small groups closely similar 
in terms of participant characteristics at all stages of the trial.  Minimisation offers the only acceptable alternative to randomisation, and some have argued that it is 
superior.145 On the other hand, minimisation lacks the theoretical basis for eliminating bias on all known and unknown factors. Nevertheless, in general, trials that 
use minimisation are considered methodologically equivalent to randomised trials, even when a random element is not incorporated.
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in bottles and consecutively numbered for each woman 
according to the randomisation schedule. Each woman 
was assigned an order number and received the capsules 
in the corresponding prepacked bottle.”146
“The allocation sequence was concealed from the 
researcher (JR) enrolling and assessing participants in 
sequentially numbered, opaque, sealed and stapled 
envelopes. Aluminium foil inside the envelope was used 
to render the envelope impermeable to intense light. To 
prevent subversion of the allocation sequence, the name 
and date of birth of the participant was written on the 
envelope and a video tape made of the sealed envelope 
with participant details visible. Carbon paper inside the 
envelope transferred the information onto the allocation 
card inside the envelope and a second researcher (CC) later 
viewed video tapes to ensure envelopes were still sealed 
when participants’ names were written on them. Corre‑
sponding envelopes were opened only after the enrolled 
participants completed all baseline assessments and it was 
time to allocate the intervention.”147
Explanation—Item 8a discussed generation of an unpredict‑
able sequence of assignments. Of considerable importance is 
how this sequence is applied when participants are enrolled 
into the trial (see box 1). A generated allocation schedule 
should be implemented by using allocation concealment,23 a 
critical mechanism that prevents foreknowledge of treatment 
assignment and thus shields those who enroll participants 
from being influenced by this knowledge. The decision to 
accept or reject a participant should be made, and informed 
consent should be obtained from the participant, in igno‑
rance of the next assignment in the sequence.148
The allocation concealment should not be confused with 
blinding (see item 11). Allocation concealment seeks to pre‑
vent selection bias, protects the assignment sequence until 
allocation, and can always be successfully implemented.2 
In contrast, blinding seeks to prevent performance and 
ascertainment bias, protects the sequence after allocation, 
and cannot always be implemented.23 Without adequate 
allocation concealment, however, even random, unpredict‑
able assignment sequences can be subverted.2 149
Centralised or “third‑party” assignment is especially 
desirable. Many good allocation concealment mechanisms 
incorporate external involvement. Use of a pharmacy or 
central telephone randomisation system are two common 
techniques. Automated assignment systems are likely to 
become more common.150 When external involvement is 
not feasible, an excellent method of allocation conceal‑
ment is the use of numbered containers. The interventions 
(often drugs) are sealed in sequentially numbered iden‑
tical containers according to the allocation sequence.151 
Enclosing assignments in sequentially numbered, opaque, 
sealed envelopes can be a good allocation concealment 
mechanism if it is developed and monitored diligently. 
This method can be corrupted, however, particularly if it 
is poorly executed. Investigators should ensure that the 
envelopes are opaque when held to the light, and opened 
sequentially and only after the participant’s name and 
other details are written on the appropriate envelope.143
A number of methodological studies provide empirical 
evidence to support these precautions.152 153 Trials in which 
the allocation sequence had been inadequately or unclearly 
cohort of PubMed indexed trials in 2006.17 In more than 
90% of these cases, researchers used a random number 
generator on a computer or a random number table.
Item 8b. Type of randomisation; details of any restriction (such as 
blocking and block size)
Examples—“Randomization sequence was created using 
Stata 9.0 (StataCorp, College Station, TX) statistical soft‑
ware and was stratified by center with a 1:1 allocation 
using random block sizes of 2, 4, and 6.”137
“Participants were randomly assigned following simple 
randomization procedures (computerized random num‑
bers) to 1 of 2 treatment groups.”138
Explanation—In trials of several hundred participants or 
more simple randomisation can usually be trusted to gener‑
ate similar numbers in the two trial groups139 and to gener‑
ate groups that are roughly comparable in terms of known 
and unknown prognostic variables.140 For smaller trials 
(see item 7a)—and even for trials that are not intended to be 
small, as they may stop before reaching their target size—
some restricted randomisation (procedures to help achieve 
balance between groups in size or characteristics) may be 
useful (see box 2).
It is important to indicate whether no restriction was used, 
by stating such or by stating that “simple randomisation” 
was done. Otherwise, the methods used to restrict the ran‑
domisation, along with the method used for random selec‑
tion, should be specified. For block randomisation, authors 
should provide details on how the blocks were generated (for 
example, by using a permuted block design with a compu‑
ter random number generator), the block size or sizes, and 
whether the block size was fixed or randomly varied. If the 
trialists became aware of the block size(s), that information 
should also be reported as such knowledge could lead to code 
breaking. Authors should specify whether stratification was 
used, and if so, which factors were involved (such as recruit‑
ment site, sex, disease stage), the categorisation cut‑off values 
within strata, and the method used for restriction. Although 
stratification is a useful technique, especially for smaller tri‑
als, it is complicated to implement and may be impossible if 
many stratifying factors are used. If minimisation (see box 
2) was used, it should be explicitly identified, as should the 
variables incorporated into the scheme. If used, a random 
element should be indicated.
Only 9% of 206 reports of trials in specialty journals23 and 
39% of 80 trials in general medical journals reported use of 
stratification.32 In each case, only about half of the reports 
mentioned the use of restricted randomisation. However, 
these studies and that of Adetugbo and Williams8 found 
that the sizes of the treatment groups in many trials were the 
same or quite similar, yet blocking or stratification had not 
been mentioned. One possible explanation for the close bal‑
ance in numbers is underreporting of the use of restricted 
randomisation.
Item 9. Mechanism used to implement the random allocation 
sequence (such as sequentially numbered containers), describing 
any steps taken to conceal the sequence until interventions were 
assigned
Examples—“The doxycycline and placebo were in capsule 
form and identical in appearance. They were prepacked 
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Explanation—As noted in item 9, concealment of the allo‑
cated intervention at the time of enrolment is especially 
important. Thus, in addition to knowing the methods used, 
it is also important to understand how the random sequence 
was implemented—specifically, who generated the alloca‑
tion sequence, who enrolled participants, and who assigned 
participants to trial groups.
The process of randomising participants into a trial has 
three different steps: sequence generation, allocation con‑
cealment, and implementation (see box 3). Although the 
same people may carry out more than one process under 
each heading, investigators should strive for complete sepa‑
ration of the people involved with generation and allocation 
concealment from the people involved in the implementation 
of assignments. Thus, if someone is involved in the sequence 
generation or allocation concealment steps, ideally they 
should not be involved in the implementation step.
Even with flawless sequence generation and allocation 
concealment, failure to separate creation and concealment 
of the allocation sequence from assignment to study group 
may introduce bias. For example, the person who generated 
an allocation sequence could retain a copy and consult it 
when interviewing potential participants for a trial. Thus, 
that person could bias the enrolment or assignment proc‑
ess, regardless of the unpredictability of the assignment 
sequence. Investigators must then ensure that the assign‑
ment schedule is unpredictable and locked away (such as 
in a safe deposit box in a building rather inaccessible to the 
enrolment location) from even the person who generated it. 
The report of the trial should specify where the investigators 
stored the allocation list.
Item 11a. If done, who was blinded after assignment to interventions 
(for example, participants, care providers, those assessing outcomes) 
and how
Examples—“Whereas patients and physicians allocated 
to the intervention group were aware of the allocated arm, 
outcome assessors and data analysts were kept blinded to 
the allocation.”156
“Blinding and equipoise were strictly maintained by 
emphasising to intervention staff and participants that each 
diet adheres to healthy principles, and each is advocated 
by certain experts to be superior for long‑term weight‑loss. 
Except for the interventionists (dieticians and behavioural 
psychologists), investigators and staff were kept blind to diet 
assignment of the participants. The trial adhered to estab‑
lished procedures to maintain separation between staff 
that take outcome measurements and staff that deliver the 
intervention. Staff members who obtained outcome meas‑
urements were not informed of the diet group assignment. 
Intervention staff, dieticians and behavioural psychologists 
who delivered the intervention did not take outcome meas‑
urements. All investigators, staff, and participants were kept 
masked to outcome measurements and trial results.”157
Explanation—The term “blinding” or “masking” refers 
to withholding information about the assigned interven‑
tions from people involved in the trial who may potentially 
be influenced by this knowledge. Blinding is an important 
safeguard against bias, particularly when assessing subjec‑
tive outcomes.153
Benjamin Franklin has been credited as being the first to 
concealed yielded larger estimates of treatment effects than 
did trials in which authors reported adequate allocation 
concealment. These findings provide strong empirical evi‑
dence that inadequate allocation concealment contributes 
to bias in estimating treatment effects.
Despite the importance of the mechanism of allocation 
concealment, published reports often omit such details. 
The mechanism used to allocate interventions was omitted 
in reports of 89% of trials in rheumatoid arthritis,108 48% of 
trials in obstetrics and gynaecology journals,23 and 44% of 
trials in general medical journals.32 In a more broadly repre‑
sentative sample of all randomised trials indexed on PubMed, 
only 18% reported any allocation concealment mechanism, 
but some of those reported mechanisms were inadequate.16
Item 10. Who generated the allocation sequence, who enrolled 
participants, and who assigned participants to interventions
Examples—“Determination of whether a patient would be 
treated by streptomycin and bed‑rest (S case) or by bed‑rest 
alone (C case) was made by reference to a statistical series 
based on random sampling numbers drawn up for each 
sex at each centre by Professor Bradford Hill; the details 
of the series were unknown to any of the investigators or 
to the co‑ordinator … After acceptance of a patient by the 
panel, and before admission to the streptomycin centre, the 
appropriate numbered envelope was opened at the central 
office; the card inside told if the patient was to be an S or a 
C case, and this information was then given to the medical 
officer of the centre.”24
“Details of the allocated group were given on coloured 
cards contained in sequentially numbered, opaque, sealed 
envelopes. These were prepared at the NPEU and kept in an 
agreed location on each ward. Randomisation took place at 
the end of the 2nd stage of labour when the midwife con‑
sidered a vaginal birth was imminent. To enter a women 
into the study, the midwife opened the next consecutively 
numbered envelope.”154
“Block randomisation was by a computer generated ran‑
dom number list prepared by an investigator with no clini‑
cal involvement in the trial. We stratified by admission for 
an oncology related procedure. After the research nurse had 
obtained the patient’s consent, she telephoned a contact who 
was independent of the recruitment process for allocation 
consignment.”155
box 3 |  Steps in a typical randomisation process 
Sequence generation
Generate allocation sequence by some random procedure•	
Allocation concealment
Develop allocation concealment mechanism (such as numbered, identical bottles or •	
sequentially numbered, sealed, opaque envelopes)
Prepare the allocation concealment mechanism using the allocation sequence from the •	
sequence generation step
Implementation
Enrol participants:•	
Assess eligibility
Discuss the trial
Obtain informed consent
Enrol participant in trial
Ascertain intervention assignment (such as opening next envelope)•	
Administer intervention•	
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attrition.164 In certain trials, especially surgical trials, 
blinding of participants and surgeons is often difficult or 
impossible, but blinding of data collectors and outcome 
adjudicators is often achievable. For example, lesions can 
be photographed before and after treatment and assessed 
by an external observer.165 Regardless of whether blinding 
is possible, authors can and should always state who was 
blinded (that is, participants, healthcare providers, data 
collectors, and outcome adjudicators).
Unfortunately, authors often do not report whether 
blinding was used.166 For example, reports of 51% of 506 
trials in cystic fibrosis,167 33% of 196 trials in rheumatoid 
arthritis,108 and 38% of 68 trials in dermatology8 did not 
state whether blinding was used. Until authors of trials 
improve their reporting of blinding, readers will have dif‑
ficulty in judging the validity of the trials that they may 
wish to use to guide their clinical practice.
The term masking is sometimes used in preference to 
blinding to avoid confusion with the medical condition 
of being without sight. However, “blinding” in its meth‑
odological sense seems to be understood worldwide and 
is acceptable for reporting clinical trials.165 168
Item 11b. If relevant, description of the similarity of interventions
Example—“Jamieson Laboratories Inc provided 500‑mg 
immediate release niacin in a white, oblong, bisect caplet. 
We independently confirmed caplet content using high 
performance liquid chromatography… The placebo was 
matched to the study drug for taste, color, and size, and con‑
tained microcrystalline cellulose, silicon dioxide, dicalcium 
phosphate, magnesium stearate, and stearic acid.”172
Explanation—Just as we seek evidence of concealment to 
assure us that assignment was truly random, we seek evidence 
of the method of blinding. In trials with  blinding of participants 
or healthcare providers, authors should state the similarity of 
the characteristics of the interventions (such as appearance, 
taste, smell, and method of  administration).35 173
Some people have advocated testing for blinding by 
use blinding in a scientific experiment.158 He blindfolded 
participants so they would not know when he was applying 
mesmerism (a popular “healing fluid” of the 18th century) 
and in so doing showed that mesmerism was a sham. Based 
on this experiment, the scientific community recognised the 
power of blinding to reduce bias, and it has remained a com‑
monly used strategy in scientific experiments.
Box 4, on blinding terminology, defines the groups of 
individuals (that is, participants, healthcare providers, data 
collectors, outcome adjudicators, and data analysts) who can 
potentially introduce bias into a trial through knowledge of 
the treatment assignments. Participants may respond differ‑
ently if they are aware of their treatment assignment (such 
as responding more favourably when they receive the new 
treatment).153 Lack of blinding may also influence compli‑
ance with the intervention, use of co‑interventions, and risk 
of dropping out of the trial.
Unblinded healthcare providers may introduce similar 
biases, and unblinded data collectors may differentially 
assess outcomes (such as frequency or timing), repeat 
measurements of abnormal findings, or provide encour‑
agement during performance testing. Unblinded outcome 
adjudicators may differentially assess subjective outcomes, 
and unblinded data analysts may introduce bias through 
the choice of analytical strategies, such as the selection of 
favourable time points or outcomes, and by decisions to 
remove patients from the analyses. These biases have been 
well documented.71 153 159‑ 162
Blinding, unlike allocation concealment (see item 10), 
may not always be appropriate or possible. An example is 
a trial comparing levels of pain associated with sampling 
blood from the ear or thumb.163 Blinding is particularly 
important when outcome measures involve some subjec‑
tivity, such as assessment of pain. Blinding of data col‑
lectors and outcome adjudicators is unlikely to matter for 
objective outcomes, such as death from any cause. Even 
then, however, lack of participant or healthcare provider 
blinding can lead to other problems, such as differential 
box 4 |  Blinding terminology
In order for a technical term to have utility it must have consistency in its use and 
interpretation. Authors of trials commonly use the term “double blind” and, less 
commonly, the terms “single blind”or “triple blind.” A problem with this lexicon is 
that there is great variability in clinician interpretations and epidemiological textbook 
definitions of these terms.169 Moreover, a study of 200 RCTs reported as double blind 
found 18 different combinations of groups actually blinded when the authors of these 
trials were surveyed, and about one in every five of these trials—reported as double 
blind—did not blind participants, healthcare providers, or data collectors.170
This research shows that terms are ambiguous and, as such, authors and editors should 
abandon their use. Authors should instead explicitly report the blinding status of the 
people involved for whom blinding may influence the validity of a trial.
Healthcare providers include all personnel (for example, physicians, chiropractors, 
physiotherapists, nurses) who care for the participants during the trial. Data collectors 
are the individuals who collect data on the trial outcomes. Outcome adjudicators are 
the individuals who determine whether a participant did experience the outcomes of 
interest.
Some researchers have also advocated blinding and reporting the blinding status of 
the data monitoring committee and the manuscript writers.160 Blinding of these groups is 
uncommon, and the value of blinding them is debated.171
Sometimes one group of individuals (such as the healthcare providers) are the same 
individuals fulfilling another role in a trial (such as data collectors). Even if this is the 
case, the authors should explicitly state the blinding status of these groups to allow 
readers to judge the validity of the trial.
Fig 2 | Flow diagram of a multicentre trial of fractional flow 
reserve versus angiography for guiding percutaneous coronary 
intervention (PCI) (adapted from Tonino et al313). The diagram 
includes detailed information on the excluded participants.
1905 Patients were assessed for eligibility
1005 Underwent randomization
509 Were assigned to fractional
flow reserve guided PCI
495 Were assigned to
angiography-guided PCI
509 Were included in
intention-to-treat analysis
496 Were included in
intention-to-treat analysis
8 Were lost to follow-up11 Were lost to follow-up
909 Were not eligible
  157 Had left main artery stenosis
  217 Had extreme vessel tortuosity or calcification
  105 Did not provide consent
  86 Had contraindication for drug-eluting stent
  94 Were participating in another study
  210 Had logistic reasons
  31 Had other reasons
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access to the original data to verify the reported results” 
(www.icmje.org). It is also important to describe details of 
the statistical analysis such as intention‑to‑treat analysis 
(see box 6).
Almost all methods of analysis yield an estimate of the 
treatment effect, which is a contrast between the outcomes in 
the comparison groups. Authors should accompany this by a 
confidence interval for the estimated effect, which indicates 
a central range of uncertainty for the true treatment effect. 
The confidence interval may be interpreted as the range of 
values for the treatment effect that is compatible with the 
observed data. It is customary to present a 95% confidence 
interval, which gives the range expected to include the true 
value in 95 of 100 similar studies.
Study findings can also be assessed in terms of their sta‑
tistical significance. The P value represents the probability 
that the observed data (or a more extreme result) could have 
arisen by chance when the interventions did not truly differ. 
Actual P values (for example, P=0.003) are strongly prefer‑
able to imprecise threshold reports such as P<0.05.48 177
Standard methods of analysis assume that the data are 
“independent.” For controlled trials, this usually means that 
there is one observation per participant. Treating multiple 
observations from one participant as independent data is a 
serious error; such data are produced when outcomes can 
be measured on different parts of the body, as in dentistry 
or rheumatology. Data analysis should be based on count‑
ing each participant once178 179 or should be done by using 
more complex statistical procedures.180 Incorrect analysis of 
multiple observations per individual was seen in 123 (63%) 
of 196 trials in rheumatoid arthritis.108
Item 12b. Methods for additional analyses, such as subgroup analyses 
and adjusted analyses
Examples—“Proportions of patients responding were 
compared between treatment groups with the Mantel‑
Haenszel χ2 test, adjusted for the stratification variable, 
 methotrexate use.”103
asking participants or healthcare providers at the end of a 
trial whether they think the participant received the experi‑
mental or control intervention.174 Because participants and 
healthcare providers will usually know whether the par‑
ticipant has experienced the primary outcome, this makes 
it difficult to determine if their responses reflect failure of 
blinding or accurate assumptions about the efficacy of the 
intervention.175 Given the uncertainty this type of informa‑
tion provides, we have removed advocating reporting this 
type of testing for blinding from the CONSORT 2010 State‑
ment. We do, however, advocate that the authors report 
any known compromises in blinding. For example, authors 
should report if it was necessary to unblind any partici‑
pants at any point during the conduct of a trial.
Item 12a. Statistical methods used to compare groups for primary 
and secondary outcomes
Example—“The primary endpoint was change in body‑
weight during the 20 weeks of the study in the intention‑to‑
treat population … Secondary efficacy endpoints included 
change in waist circumference, systolic and diastolic blood 
pressure, prevalence of metabolic syndrome … We used an 
analysis of covariance (ANCOVA) for the primary endpoint 
and for secondary endpoints waist circumference, blood 
pressure, and patient‑reported outcome scores; this was sup‑
plemented by a repeated measures analysis. The ANCOVA 
model included treatment, country, and sex as fixed effects, 
and bodyweight at randomisation as covariate. We aimed to 
assess whether data provided evidence of superiority of each 
liraglutide dose to placebo (primary objective) and to orlistat 
(secondary objective).”176
Explanation—Data can be analysed in many ways, some 
of which may not be strictly appropriate in a particular 
situation. It is essential to specify which statistical pro‑
cedure was used for each analysis, and further clarifica‑
tion may be necessary in the results section of the report. 
The principle to follow is to, “Describe statistical methods 
with enough detail to enable a knowledgeable reader with 
Fig 3 | Flow diagram of minimal surgery compared with medical management for chronic gastro-oesophageal reflux disease (adapted from Grant et al196). The diagram 
shows a multicentre trial with a parallel non-randomised preference group. 
Patients in preference study (n=453)Patients randomised (n=357)
Assessed for eligibility (n=1078)
Preference medicine (n=192)
Received surgery (n=3)
Preference surgery (n=261)
Withdrawn before surgery (n=16)
Received surgery (n=218)
Declined surgery (n=25)
Surgery referred (n=2)
Allocated to medicine (n=179)
Received surgery (n=10)
Baseline questionnaire returned (n=174)Baseline questionnaire returned (n=175) Baseline questionnaire returned (n=189)Baseline questionnaire returned (n=256)
Allocated to surgery (n=178)
Withdrawn before surgery (n=20)
Received surgery (n=111)
Declined surgery (n=47)
Follow-up time equivalent to 1 year after
  surgery (n=177)
Withdrawn/lost to follow-up (n=8)
Response (n=177)
Non-response (n=7)
Analysed with Reflux QoL Score (n=163)
Follow-up time equivalent to 1 year after
  surgery (n=230)
Withdrawn/lost to follow-up (n=12)
Death (n=2)
Response (n=230)
Non-response (n=17)
Analysed with Reflux QoL Score (n=212)
Follow-up time equivalent to 1 year after
  surgery (n=164)
Withdrawn/lost to follow-up (n=5)
Death (n=1)
Response (n=164)
Non-response (n=9)
Analysed with Reflux QoL Score (n=154)
Follow-up time equivalent to 1 year after
  surgery (n=154)
Withdrawn/lost to follow-up (n=14)
Response (n=154)
Non-response (n=10)
Analysed with Reflux QoL Score (n=145)
Ineligible (n=200)
Eligible but not recruited (n=68)
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Results
Item 13. Participant flow (a diagram is strongly recommended) 
Item 13a. For each group, the numbers of participants who were 
randomly assigned, received intended treatment, and were analysed 
for the primary outcome
Examples—See figs 2 and 3.
Explanation—The design and conduct of some RCTs is 
straightforward, and the flow of participants, particularly 
were there are no losses to follow‑up or exclusions, through 
each phase of the study can be described adequately in a few 
sentences. In more complex studies, it may be difficult for 
readers to discern whether and why some participants did 
not receive the treatment as allocated, were lost to follow‑up, 
or were excluded from the analysis.51 This information is cru‑
cial for several reasons. Participants who were excluded after 
allocation are unlikely to be representative of all participants 
in the study. For example, patients may not be available for 
follow‑up evaluation because they experienced an acute exac‑
erbation of their illness or harms of treatment.22 192
Attrition as a result of loss to follow up, which is often una‑
voidable, needs to be distinguished from investigator‑deter‑
mined exclusion for such reasons as ineligibility, withdrawal 
from treatment, and poor adherence to the trial protocol. Erro‑
neous conclusions can be reached if participants are excluded 
from analysis, and imbalances in such omissions between 
groups may be especially indicative of bias.192‑194 Informa‑
tion about whether the investigators included in the analysis 
all participants who underwent randomisation, in the groups 
to which they were originally allocated (intention‑to‑treat 
analysis (see item 16 and box 6)), is therefore of particular 
importance. Knowing the number of participants who did not 
receive the intervention as allocated or did not complete treat‑
ment permits the reader to assess to what extent the estimated 
efficacy of therapy might be  underestimated in comparison 
with ideal circumstances.
If available, the number of people assessed for eligibility 
should also be reported. Although this number is relevant to 
external validity only and is arguably less important than the 
other counts,195 it is a useful indicator of whether trial par‑
ticipants were likely to be representative of all eligible par‑
ticipants.
A review of RCTs published in five leading general and 
internal medicine journals in 1998 found that reporting of the 
“Pre‑specified subgroup analyses according to antioxi‑
dant treatment assignment(s), presence or absence of prior 
CVD, dietary folic acid intake, smoking, diabetes, aspirin, 
hormone therapy, and multivitamin use were performed 
using stratified Cox proportional hazards models. These 
analyses used baseline exposure assessments and were 
restricted to participants with nonmissing subgroup data 
at baseline.”181
Explanation—As is the case for primary analyses, the 
method of subgroup analysis should be clearly specified. 
The strongest analyses are those that look for evidence of a 
difference in treatment effect in complementary subgroups 
(for example, older and younger participants), a compari‑
son known as a test of interaction.182 183 A common but 
misleading approach is to compare P values for separate 
analyses of the treatment effect in each group. It is incorrect 
to infer a subgroup effect (interaction) from one significant 
and one non‑significant P value.184 Such inferences have a 
high false positive rate.
Because of the high risk for spurious findings, subgroup 
analyses are often discouraged.14 185 Post hoc subgroup 
comparisons (analyses done after looking at the data) are 
especially likely not to be confirmed by further studies. Such 
analyses do not have great credibility.
In some studies, imbalances in participant characteristics 
are adjusted for by using some form of multiple regression 
analysis. Although the need for adjustment is much less in 
RCTs than in epidemiological studies, an adjusted analy‑
sis may be sensible, especially if one or more variables is 
thought to be prognostic.186 Ideally, adjusted analyses should 
be specified in the study protocol (see item 24). For example, 
adjustment is often recommended for any stratification vari‑
ables (see item 8b) on the principle that the analysis strat‑
egy should follow the design. In RCTs, the decision to adjust 
should not be determined by whether baseline differences 
are statistically significant (see item 16).183 187 The rationale 
for any adjusted analyses and the statistical methods used 
should be specified.
Authors should clarify the choice of variables that were 
adjusted for, indicate how continuous variables were han‑
dled, and specify whether the analysis was planned or sug‑
gested by the data.188 Reviews of published studies show 
that reporting of adjusted analyses is inadequate with regard 
to all of these aspects.188‑191
table 3 | Information required to document the flow of participants through each stage of a randomised trial 
Stage Number of people included
Number of people not included or 
excluded Rationale
Enrolment People evaluated for potential 
enrolment
People who did not meet the inclusion 
criteria or met the inclusion criteria but 
declined to be enrolled
These counts indicate whether trial participants were 
likely to be representative of all patients seen; they are 
relevant to assessment of external validity only, and 
they are often not available.
Randomisation Participants randomly assigned Crucial count for defining trial size and assessing 
whether a trial has been analysed by intention to treat
Treatment allocation Participants who completed treatment 
as allocated, by study group
Participants who did not complete 
treatment as allocated, by study group
Important counts for assessment of internal validity 
and interpretation of results; reasons for not receiving 
treatment as allocated should be given.
Follow-up Participants who completed treatment 
as allocated, by study group
Participants who did not complete 
treatment as allocated, by study group
Important counts for assessment of internal validity 
and interpretation of results; reasons for not 
completing treatment or follow-up should be given.Participants who completed follow-up 
as planned, by study group
Participants who did not complete 
follow-up as planned, by study group
Analysis Participants included in main 
analysis, by study group
Participants excluded from main 
analysis, by study group
Crucial count for assessing whether a trial has been 
analysed by intention to treat; reasons for excluding 
participants should be given.
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of the flow of participants through a trial, as recommended 
by CONSORT. This study informed the design of the revised 
flow diagram in the revised CONSORT statement.52‑54 The sug‑
gested template is shown in fig 1, and the counts required are 
described in detail in table 3.
Some information, such as the number of individuals 
assessed for eligibility, may not always be known,14 and, 
depending on the nature of a trial, some counts may be more 
relevant than others. It will sometimes be useful or neces‑
sary to adapt the structure of the flow diagram to a particular 
trial. In some situations, other information may usefully be 
added. For example, the flow diagram of a parallel group trial 
of minimal surgery compared with medical management for 
chronic gastro‑oesophageal reflux also included a parallel 
non‑randomised preference group (see fig 3).196 
The exact form and content of the flow diagram may be var‑
ied according to specific features of a trial. For example, many 
trials of surgery or vaccination do not include the possibility 
of discontinuation. Although CONSORT strongly recommends 
using this graphical device to communicate participant flow 
throughout the study, there is no specific, prescribed format.
Item 13b. For each group, losses and exclusions after randomisation, 
together with reasons
Examples—“There was only one protocol deviation, in a 
woman in the study group. She had an abnormal pelvic 
measurement and was scheduled for elective caesarean sec‑
tion. However, the attending obstetrician judged a trial of 
labour acceptable; caesarean section was done when there 
was no progress in the first stage of labour.”197
“The monitoring led to withdrawal of nine centres, in 
which existence of some patients could not be proved, 
or other serious violations of good clinical practice had 
occurred.”198
Explanation—Some protocol deviations may be reported in 
flow of participants was often incomplete, particularly with 
regard to the number of participants receiving the allocated 
intervention and the number lost to follow‑up.51 Even infor‑
mation as basic as the number of participants who underwent 
randomisation and the number excluded from analyses was 
not available in up to 20% of articles.51 Reporting was con‑
siderably more thorough in articles that included a diagram 
box 5 | Early stopping
RCTs can end when they reach their sample size goal, their event count goal, their length of 
follow-up goal, or when they reach their scheduled date of closure. In these situations the 
trial will stop in a manner independent of its results, and stopping is unlikely to introduce 
bias in the results. Alternatively, RCTs can stop earlier than planned because of the result 
of an interim analysis showing larger than expected benefit or harm on the experimental 
intervention. Also RCTs can stop earlier than planned when investigators find evidence of 
no important difference between experimental and control interventions (that is, stopping 
for futility). In addition, trials may stop early because the trial becomes unviable: funding 
vanishes, researchers cannot access eligible patients or study interventions, or the results of 
other studies make the research question irrelevant.
Full reporting of why a trial ended is important for evidence based decision making (see item 
14b). Researchers examining why 143 trials stopped early for benefit found that many failed 
to report key methodological information regarding how the decision to stop was reached—
the planned sample size (n=28), interim analysis after which the trial was stopped (n=45), or 
whether a stopping rule informed the decision (n=48).134 Item 7b of the checklist requires the 
reporting of timing of interim analyses, what triggered them, how many took place, whether 
these were planned or ad hoc, and whether there were statistical guidelines and stopping 
rules in place a priori. Furthermore, it is helpful to know whether an independent data 
monitoring committee participated in the analyses (and who composed it, with particular 
attention to the role of the funding source) and who made the decision to stop. Often the data 
safety and monitoring committee makes recommendations and the funders (sponsors) or the 
investigators make the decision to stop.
Trials that stop early for reasons apparently independent of trial findings, and trials that 
reach their planned termination, are unlikely to introduce bias by stopping.207 In these cases, 
the authors should report whether interim analyses took place and whether these results 
were available to the funder.
The push for trials that change the intervention in response to interim results, thus enabling 
a faster evaluation of promising interventions for rapidly evolving and fatal conditions, will 
require even more careful reporting of the process and decision to stop trials early.208
table 4 | Example of reporting baseline demographic and clinical characteristics.* (Adapted from table 1 of Yusuf et al209)
Telmisartan (N=2954) Placebo (N=2972)
Age (years) 66.9 (7.3) 66.9 (7.4)
Sex (female) 1280 (43.3%) 1267 (42.6%)
Smoking status:
 Current 293 (9.9%) 289 (9.7%)
 Past 1273 (43.1%) 1283 (43.2%)
Ethnic origin:
 Asian 637 (21.6%) 624 (21.0%)
 Arab 37 (1.3%) 40 (1.3%)
 African 51 (1.7%) 55 (1.9%)
 European 1801 (61.0%) 1820 (61.2%)
 Native or Aboriginal 390 (13.2%) 393 (13.2%)
 Other 38 (1.3%) 40 (1.3%)
Blood pressure (mm Hg) 140.7 (16.8/81.8) (10.1) 141.3 (16.4/82.0) (10.2)
Heart rate (beats per min) 68.8 (11.5) 68.8 (12.1)
Cholesterol (mmol/l):
 Total 5.09 (1.18) 5.08 (1.15)
 LDL 3.02 (1.01) 3.03 (1.02)
 HDL 1.27 (0.37) 1.28 (0.41)
Coronary artery disease 2211 (74.8%) 2207 (74.3%)
Myocardial infarction 1381 (46.8%) 1360 (45.8%)
Angina pectoris 1412 (47.8%) 1412 (47.5%)
Peripheral artery disease 349 (11.8%) 323 (10.9%)
Hypertension 2259 (76.5%) 2269 (76.3%)
Diabetes 1059 (35.8%) 1059 (35.6%)
*Data are means (SD) or numbers (%).
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unplanned interim analyses after very few events accrue 
using no statistical guidelines run a high risk of “catching” 
the data at a random extreme, which likely represents a 
large overestimate of treatment benefit.204
Readers will likely draw weaker inferences from a trial 
that was truncated in a data‑driven manner versus one that 
reports its findings after reaching a goal independent of 
results. Thus, RCTs should indicate why the trial came to 
an end (see box 5). The report should also disclose factors 
extrinsic to the trial that affected the decision to stop the 
trial, and who made the decision to stop the trial, including 
reporting the role the funding agency played in the delib‑
erations and in the decision to stop the trial.134
A systematic review of 143 RCTs stopped earlier than 
planned for benefit found that these trials reported stop‑
ping after accruing a median of 66 events, estimated a 
median relative risk of 0.47 and a strong relation between 
the number of events accrued and the size of the effect, 
with smaller trials with fewer events yielding the largest 
treatment effects (odds ratio 31, 95% confidence interval 
12 to 82).134 While an increasing number of trials published 
in high impact medical journals report stopping early, only 
0.1% of trials reported stopping early for benefit, which 
contrasts with estimates arising from simulation studies205 
and surveys of data safety and monitoring committees.206 
Thus, many trials accruing few participants and reporting 
large treatment effects may have been stopped earlier than 
planned but failed to report this action.
Item 15. A table showing baseline demographic and clinical 
characteristics for each group
Example—See table 4
Explanation—Although the eligibility criteria (see item 4a) 
indicate who was eligible for the trial, it is also important to 
know the characteristics of the participants who were actu‑
ally included. This information allows readers, especially 
clinicians, to judge how relevant the results of a trial might 
be to an individual patient.
Randomised trials aim to compare groups of participants 
that differ only with respect to the intervention (treatment). 
Although proper random assignment prevents selection 
bias, it does not guarantee that the groups are equivalent 
at baseline. Any differences in baseline characteristics 
are, however, the result of chance rather than bias.32 The 
study groups should be compared at baseline for important 
demographic and clinical characteristics so that readers 
can assess how similar they were. Baseline data are espe‑
cially valuable for outcomes that can also be measured at 
the start of the trial (such as blood pressure).
Baseline information is most efficiently presented in 
a table (see table 4). For continuous variables, such as 
weight or blood pressure, the variability of the data should 
be reported, along with average values. Continuous vari‑
ables can be summarised for each group by the mean 
and standard deviation. When continuous data have an 
asymmetrical distribution, a preferable approach may be 
to quote the median and a centile range (such as the 25th 
and 75th centiles).177 Standard errors and confidence inter‑
vals are not appropriate for describing variability—they are 
inferential rather than descriptive statistics. Variables with 
a small number of ordered categories (such as stages of dis‑
the flow diagram (see item 13a)—for example, participants 
who did not receive the intended intervention. If participants 
were excluded after randomisation (contrary to the inten‑
tion‑to‑treat principle) because they were found not to meet 
eligibility criteria (see item 16), they should be included in 
the flow diagram. Use of the term “protocol deviation” in 
published articles is not sufficient to justify exclusion of 
participants after randomisation. The nature of the protocol 
deviation and the exact reason for excluding participants 
after randomisation should always be reported.
Item 14a. Dates defining the periods of recruitment and 
follow-up
Example—“Age‑eligible participants were recruited … 
from February 1993 to September 1994 … Participants 
attended clinic visits at the time of randomisation (base‑
line) and at 6‑month intervals for 3 years.”199
Explanation—Knowing when a study took place and 
over what period participants were recruited places the 
study in historical context. Medical and surgical thera‑
pies, including concurrent therapies, evolve continuously 
and may affect the routine care given to participants dur‑
ing a trial. Knowing the rate at which participants were 
recruited may also be useful, especially to other investi‑
gators.
The length of follow‑up is not always a fixed period 
after randomisation. In many RCTs in which the outcome 
is time to an event, follow‑up of all participants is ended 
on a specific date. This date should be given, and it is also 
useful to report the minimum, maximum, and median 
duration of follow‑up.200 201
A review of reports in oncology journals that used sur‑
vival analysis, most of which were not RCTs, 201 found 
that nearly 80% (104 of 132 reports) included the start‑
ing and ending dates for accrual of patients, but only 
24% (32 of 132 reports) also reported the date on which 
follow‑up ended.
Item 14b. Why the trial ended or was stopped
Examples—“At the time of the interim analysis, the total 
follow‑up included an estimated 63% of the total number 
of patient‑years that would have been collected at the end of 
the study, leading to a threshold value of 0.0095, as deter‑
mined by the Lan‑DeMets alpha‑spending function method 
… At the interim analysis, the RR was 0.37 in the intervention 
group, as compared with the control group, with a p value 
of 0.00073, below the threshold value. The Data and Safety 
Monitoring Board advised the investigators to interrupt the 
trial and offer circumcision to the control group, who were 
then asked to come to the investigation centre, where MC 
(medical circumcision) was advised and proposed … Because 
the study was interrupted, some participants did not have a 
full follow‑up on that date, and their visits that were not yet 
completed are described as “planned” in this article.”202
“In January 2000, problems with vaccine supply neces‑
sitated the temporary nationwide replacement of the 
whole cell component of the combined DPT/Hib vaccine 
with acellular pertussis vaccine. As this vaccine has a dif‑
ferent local reactogenicity profile, we decided to stop the 
trial early.”203
Explanation—Arguably, trialists who arbitrarily conduct 
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significance tests assess the probability that observed base‑
line differences could have occurred by chance; however, 
we already know that any differences are caused by chance. 
Tests of baseline differences are not necessarily wrong, just 
illogical.211 Such hypothesis testing is superfluous and can 
mislead investigators and their readers. Rather, comparisons 
at baseline should be based on consideration of the prog‑
nostic strength of the variables measured and the size of any 
chance imbalances that have occurred.211
Item 16. For each group, number of participants (denominator) 
included in each analysis and whether the analysis was by original 
assigned groups
Examples—“The primary analysis was intention‑to‑treat and 
involved all patients who were randomly assigned.”212
“One patient in the alendronate group was lost to follow 
up; thus data from 31 patients were available for the inten‑
tion‑to‑treat analysis. Five patients were considered protocol 
violators … consequently 26 patients remained for the per‑
protocol analyses.”213
Explanation—The number of participants in each group is 
an essential element of the analyses. Although the flow dia‑
gram (see item 13a) may indicate the numbers of participants 
analysed, these numbers often vary for different outcome 
measures. The number of participants per group should be 
given for all analyses. For binary outcomes, (such as risk ratio 
and risk difference) the denominators or event rates should 
also be reported. Expressing results as fractions also aids the 
reader in assessing whether some of the randomly assigned 
participants were excluded from the analysis. It follows that 
results should not be presented solely as summary measures, 
such as relative risks.
ease I to IV) should not be treated as continuous variables; 
instead, numbers and proportions should be reported for 
each category.48 177
Unfortunately significance tests of baseline differences are 
still common23 32 210; they were reported in half of 50 RCTs 
trials published in leading general journals in 1997.183 Such 
box 6 | Intention-to-treat analysis
The special strength of the RCT is the avoidance of bias when allocating interventions to trial participants (see box 1). That strength allows strong inferences 
about cause and effect that are not justified with other study designs. In order to preserve fully the huge benefit of randomisation we should include all 
randomised participants in the analysis, all retained in the group to which they were allocated. Those two conditions define an “intention-to-treat” analysis, 
which is widely recommended as the preferred analysis strategy.18 223 Intention-to-treat analysis corresponds to analysing the groups exactly as randomised. 
Strict intention-to-treat analysis is often hard to achieve for two main reasons—missing outcomes for some participants and non-adherence to the trial protocol.
Missing outcomes
Many trialists exclude patients without an observed outcome. Often this is reasonable, but once any randomised participants are excluded the analysis is not 
strictly an intention-to-treat analysis. Indeed, most randomised trials have some missing observations. Trialists effectively must choose between omitting 
the participants without final outcome data or imputing their missing outcome data.225 A “complete case” (or “available case”) analysis includes only those 
whose outcome is known. While a few missing outcomes will not cause a problem, in half of trials more than 10% of randomised patients may have missing 
outcomes.226 This common approach will lose power by reducing the sample size, and bias may well be introduced if being lost to follow-up is related to a 
patient’s response to treatment. There should be concern when the frequency or the causes of dropping out differ between the intervention groups.
Participants with missing outcomes can be included in the analysis only if their outcomes are imputed (that is, their outcomes are estimated from other 
information that was collected). Imputation of the missing data allows the analysis to conform to intention-to-treat analysis but requires strong assumptions, 
which may be hard to justify.227 Simple imputation methods are appealing, but their use may be inadvisable. In particular, a widely used method is “last 
observation carried forward” in which missing final values of the outcome variable are replaced by the last known value before the participant was lost to follow 
up. This is appealing through its simplicity, but the method may introduce bias,228 and no allowance is made for the uncertainty of imputation.229 Many authors 
have severely criticised last observation carried forward.229-231
Non-adherence to the protocol
A separate issue is that the trial protocol may not have been followed fully for some trial participants. Common examples are participants who did not meet the 
inclusion criteria (such as wrong diagnosis, too young), received a proscribed co-intervention, did not take all the intended treatment, or received a different 
treatment or no intervention. The simple way to deal with any protocol deviations is to ignore them: all participants can be included in the analysis regardless of 
adherence to the protocol, and this is the intention-to-treat approach. Thus, exclusion of any participants for such reasons is incompatible with intention-to-treat 
analysis.
The term “modified intention-to-treat” is quite widely used to describe an analysis that excludes participants who did not adequately adhere to the protocol, 
in particular those who did not receive a defined minimum amount of the intervention.232 An alternative term is “per protocol.” Though a per protocol analysis 
may be appropriate in some settings, it should be properly labelled as a non-randomised, observational comparison. Any exclusion of patients from the analysis 
compromises the randomisation and may lead to bias in the results.
Like “intention-to-treat,” none of these other labels reliably clarifies exactly which patients were included. Thus, in the CONSORT checklist we have dropped the 
specific request for intention-to-treat analysis in favour of a clear description of exactly who was included in each analysis.
table 5 | Example of reporting of summary results for each study group (binary outcomes).* 
(Adapted from table 2 of Mease et al103)
Endpoint
Number (%)
Risk difference (95% CI)Etanercept (n=30) Placebo (n=30)
Primary endpoint
Achieved PsARC at 12 
weeks
26 (87) 7 (23) 63% (44 to 83)
Secondary endpoint
Proportion of patients 
meeting ACR criteria:
 ACR20 22 (73) 4 (13) 60% (40 to 80)
 ACR50 15 (50) 1 (3) 47% (28 to 66)
 ACR70 4 (13) 0 (0) 13% (1 to 26)
*See also example for item 6a. 
PsARC=psoriatic arthritis response criteria. ACR=American College of Rheumatology.
table 6 | Example of reporting of summary results for each study group (continuous outcomes). 
(Adapted from table 3 of van Linschoten234)
Exercise therapy (n=65) Control (n=66) Adjusted 
difference* (95% 
CI) at 12 months
Baseline 
(mean (SD))
12 months (mean 
(SD))
Baseline (mean 
(SD))
12 months 
(mean (SD))
Function score 
(0-100)
64.4 (13.9) 83.2 (14.8) 65.9 (15.2) 79.8 (17.5) 4.52 (−0.73 to 
9.76)
Pain at rest 
(0-100)
4.14 (2.3) 1.43 (2.2) 4.03 (2.3) 2.61 (2.9) −1.29 (−2.16 to 
−0.42)
Pain on activity 
(0-100)
6.32 (2.2) 2.57 (2.9) 5.97 (2.3) 3.54 (3.38) −1.19 (−2.22 to 
−0.16)
*Function score adjusted for baseline, age, and duration of symptoms.
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with other aspects of good study design and reporting, such 
as describing a sample size calculation.224
Item 17a. For each primary and secondary outcome, results for each 
group, and the estimated effect size and its precision (such as 95% 
confidence interval)
Examples—See tables 5 and 6.
Explanation—For each outcome, study results should be 
reported as a summary of the outcome in each group (for 
example, the number of participants with or without the 
event and the denominators, or the mean and standard 
deviation of measurements), together with the contrast 
between the groups, known as the effect size. For binary 
outcomes, the effect size could be the risk ratio (relative 
risk), odds ratio, or risk difference; for survival time data, it 
could be the hazard ratio or difference in median survival 
time; and for continuous data, it is usually the difference in 
means. Confidence intervals should be presented for the con‑
trast between groups. A common error is the presentation of 
separate confidence intervals for the outcome in each group 
rather than for the treatment effect.233 Trial results are often 
more clearly displayed in a table rather than in the text, as 
shown in tables 5 and 6.
For all outcomes, authors should provide a confidence 
interval to indicate the precision (uncertainty) of the esti‑
mate.48 235 A 95% confidence interval is conventional, but 
occasionally other levels are used. Many journals require or 
strongly encourage the use of confidence intervals.236 They 
are especially valuable in relation to differences that do not 
meet conventional statistical significance, for which they 
often indicate that the result does not rule out an impor‑
tant clinical difference. The use of confidence intervals 
has increased markedly in recent years, although not in all 
medical specialties.233 Although P values may be provided 
in addition to confidence intervals, results should not be 
reported solely as P values.237 238 Results should be reported 
for all planned primary and secondary end points, not just 
for analyses that were statistically significant or “interest‑
ing.” Selective reporting within a study is a widespread and 
serious problem.55 57 In trials in which interim analyses were 
performed, interpretation should focus on the final results at 
the close of the trial, not the interim results.239
For both binary and survival time data, expressing the 
results also as the number needed to treat for benefit or 
harm can be helpful (see item 21).240 241
Item 17b. For binary outcomes, presentation of both absolute and 
relative effect sizes is recommended
Example—“The risk of oxygen dependence or death was 
reduced by 16% (95% CI 25% to 7%). The absolute differ‑
ence was −6.3% (95% CI −9.9% to −2.7%); early adminis‑
tration to an estimated 16 babies would therefore prevent 1 
baby dying or being long‑term dependent on oxygen” (also 
see table 7).242
Explanation—When the primary outcome is binary, both 
the relative effect (risk ratio (relative risk) or odds ratio) and 
the absolute effect (risk difference) should be reported (with 
confidence intervals), as neither the relative measure nor the 
absolute measure alone gives a complete picture of the effect 
and its implications. Different audiences may prefer either 
relative or absolute risk, but both doctors and lay people 
Participants may sometimes not receive the full interven‑
tion, or some ineligible patients may have been randomly 
allocated in error. One widely recommended way to handle 
such issues is to analyse all participants according to their 
original group assignment, regardless of what subsequently 
occurred (see box 6). This “intention‑to‑treat” strategy is not 
always straightforward to implement. It is common for some 
patients not to complete a study—they may drop out or be 
withdrawn from active treatment—and thus are not assessed 
at the end. If the outcome is mortality, such patients may 
be included in the analysis based on register information, 
whereas imputation techniques may need to be used if other 
outcome data are missing. The term “intention‑to‑treat analy‑
sis” is often inappropriately used—for example, when those 
who did not receive the first dose of a trial drug are excluded 
from the analyses.18
Conversely, analysis can be restricted to only participants 
who fulfil the protocol in terms of eligibility, interventions, and 
outcome assessment. This analysis is known as an “on‑treat‑
ment” or “per protocol” analysis. Excluding participants from 
the analysis can lead to erroneous conclusions. For example, 
in a trial that compared medical with surgical therapy for 
carotid stenosis, analysis limited to participants who were 
available for follow‑up showed that surgery reduced the risk 
for transient ischaemic attack, stroke, and death. However, 
intention‑to‑treat analysis based on all participants as origi‑
nally assigned did not show a superior effect of surgery.214
Intention‑to‑treat analysis is generally favoured because 
it avoids bias associated with non‑random loss of par‑
ticipants.215‑217 Regardless of whether authors use the term 
“intention‑to‑treat,” they should make clear which and how 
many participants are included in each analysis (see item 
13). Non‑compliance with assigned therapy may mean that 
the intention‑to‑treat analysis underestimates the potential 
benefit of the treatment, and additional analyses, such as a 
per protocol analysis, may therefore be considered.218 219 It 
should be noted, however, that such analyses are often con‑
siderably flawed.220
In a review of 403 RCTs published in 10 leading medical 
journals in 2002, 249 (62%) reported the use of intention‑
to‑treat analysis for their primary analysis. This proportion 
was higher for journals adhering to the CONSORT state‑
ment (70% v 48%). Among articles that reported the use 
of intention‑to‑treat analysis, only 39% actually analysed 
all participants as randomised, with more than 60% of arti‑
cles having missing data in their primary analysis.221 Other 
studies show similar findings.18 222 223 Trials with no reported 
exclusions are methodologically weaker in other respects 
than those that report on some excluded participants,173 
strongly indicating that at least some researchers who have 
excluded participants do not report it. Another study found 
that reporting an intention‑to‑treat analysis was associated 
table 7 | Example of reporting both absolute and relative effect sizes. (Adapted from table 3 of 
The OSIRIS Collaborative Group242)
Primary outcome
Percentage (No)
Risk ratio (95% CI)
Risk difference 
(95% CI)
Early 
administration 
(n=1344)
Delayed selective 
administration 
(n=1346)
Death or oxygen 
dependence at “expected 
date of delivery”
31.9 (429) 38.2 (514) 0.84 (0.75 to 0.93) −6.3 (−9.9 to −2.7)
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made for nominated baseline variables by using analysis 
of covariance.187 Adjustment for variables because they dif‑
fer significantly at baseline is likely to bias the estimated 
treatment effect.187 A survey found that unacknowledged 
discrepancies between protocols and publications were 
found for all 25 trials reporting subgroup analyses and for 
23 of 28 trials reporting adjusted analyses.92
Item 19. All important harms or unintended effects in each group
For specific guidance see CONSORT for harms.42
Example—“The proportion of patients experiencing any 
adverse event was similar between the rBPI21 [recombinant 
bactericidal/permeability‑increasing protein] and placebo 
groups: 168 (88.4%) of 190 and 180 (88.7%) of 203, respec‑
tively, and it was lower in patients treated with rBPI21 than 
in those treated with placebo for 11 of 12 body systems … the 
proportion of patients experiencing a severe adverse event, 
as judged by the investigators, was numerically lower in the 
rBPI21 group than the placebo group: 53 (27.9%) of 190 
versus 74 (36.5%) of 203 patients, respectively. There were 
only three serious adverse events reported as drug‑related 
and they all occurred in the placebo group.”250
Explanation—Readers need information about the harms as 
well as the benefits of interventions to make rational and bal‑
anced decisions. The existence and nature of adverse effects 
can have a major impact on whether a particular interven‑
tion will be deemed acceptable and useful. Not all reported 
adverse events observed during a trial are necessarily a con‑
sequence of the intervention; some may be a consequence 
of the condition being treated. Randomised trials offer the 
best approach for providing safety data as well as efficacy 
data, although they cannot detect rare harms.
Many reports of RCTs provide inadequate information 
on adverse events. A survey of 192 drug trials published 
from 1967 to 1999 showed that only 39% had adequate 
reporting of clinical adverse events and 29% had adequate 
reporting of laboratory defined toxicity.72 More recently, a 
comparison between the adverse event data submitted 
to the trials database of the National Cancer Institute, 
which sponsored the trials, and the information reported 
in journal articles found that low grade adverse events 
were underreported in journal articles. High grade events 
(Common Toxicity Criteria grades 3 to 5) were reported 
inconsistently in the articles, and the information regard‑
ing attribution to investigational drugs was incomplete.251 
Moreover, a review of trials published in six general medi‑
cal journals in 2006 to 2007 found that, although 89% of 
133 reports mentioned adverse events, no information on 
severe adverse events and withdrawal of patients due to 
an adverse event was given on 27% and 48% of articles, 
respectively.252
An extension of the CONSORT statement has been devel‑
oped to provide detailed recommendations on the report‑
ing of harms in randomised trials.42 Recommendations 
and examples of appropriate reporting are freely available 
from the CONSORT website (www.consort‑statement.org). 
They complement the CONSORT 2010 Statement and 
should be consulted, particularly if the study of harms was 
a key objective. Briefly, if data on adverse events were col‑
lected, events should be listed and defined, with reference 
to standardised criteria where appropriate. The methods 
tend to overestimate the effect when it is presented in terms 
of relative risk.243‑245 The size of the risk difference is less gen‑
eralisable to other populations than the relative risk since it 
depends on the baseline risk in the unexposed group, which 
tends to vary across populations. For diseases where the out‑
come is common, a relative risk near unity might indicate 
clinically important differences in public health terms. In 
contrast, a large relative risk when the outcome is rare may 
not be so important for public health (although it may be 
important to an individual in a high risk category).
Item 18. Results of any other analyses performed, including 
subgroup analyses and adjusted analyses, distinguishing pre-
specified from exploratory
Example—“On the basis of a study that suggested periop‑
erative β‑blocker efficacy might vary across baseline risk, 
we prespecified our primary subgroup analysis on the 
basis of the revised cardiac risk index scoring system. We 
also did prespecified secondary subgroup analyses based 
on sex, type of surgery, and use of an epidural or spinal 
anaesthetic. For all subgroup analyses, we used Cox pro‑
portional hazard models that incorporated tests for inter‑
actions, designated to be significant at p<0.05 … Figure 3 
shows the results of our prespecified subgroup analyses 
and indicates consistency of effects … Our subgroup analy‑
ses were underpowered to detect the modest differences 
in subgroup effects that one might expect to detect if there 
was a true subgroup effect.”100
Explanation—Multiple analyses of the same data create a 
risk for false positive findings.246 Authors should resist the 
temptation to perform many subgroup analyses.183 185 247 
Analyses that were prespecified in the trial protocol (see item 
24) are much more reliable than those suggested by the data, 
and therefore authors should report which analyses were 
prespecified. If subgroup analyses were undertaken, authors 
should report which subgroups were examined, why, if they 
were prespecified, and how many were prespecified. Selec‑
tive reporting of subgroup analyses could lead to bias.248 
When evaluating a subgroup the question is not whether the 
subgroup shows a statistically significant result but whether 
the subgroup treatment effects are significantly different 
from each other. To determine this, a test of interaction is 
helpful, although the power for such tests is typically low. If 
formal evaluations of interaction are undertaken (see item 
12b) they should be reported as the estimated difference in 
the intervention effect in each subgroup (with a confidence 
interval), not just as P values.
In one survey, 35 of 50 trial reports included subgroup 
analyses, of which only 42% used tests of interaction.183 It 
was often difficult to determine whether subgroup analyses 
had been specified in the protocol. In another survey of sur‑
gical trials published in high impact journals, 27 of 72 trials 
reported 54 subgroup analyses, of which 91% were post hoc 
and only 6% of subgroup analyses used a test of interaction 
to assess whether a subgroup effect existed.249
Similar recommendations apply to analyses in which 
adjustment was made for baseline variables. If done, both 
unadjusted and adjusted analyses should be reported. 
Authors should indicate whether adjusted analyses, includ‑
ing the choice of variables to adjust for, were planned. Ide‑
ally, the trial protocol should state whether adjustment is 
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able insight into whether the trial result is compatible with a 
clinically important effect, regardless of the P value.120
Authors should exercise special care when evaluating 
the results of trials with multiple comparisons. Such mul‑
tiplicity arises from several interventions, outcome meas‑
ures, time points, subgroup analyses, and other factors. In 
such circumstances, some statistically significant findings 
are likely to result from chance alone.
Item 21. Generalisability (external validity, applicability) of the 
trial findings
Examples—“As the intervention was implemented for both 
sexes, all ages, all types of sports, and at different levels of 
sports, the results indicate that the entire range of athletes, 
from young elite to intermediate and recreational senior 
athletes, would benefit from using the presented training 
programme for the prevention of recurrences of ankle sprain. 
By including non‑medically treated and medically treated 
athletes, we covered a broad spectrum of injury severity. 
This suggests that the present training programme can be 
implemented in the treatment of all athletes. Furthermore, 
as it is reasonable to assume that ankle sprains not related to 
sports are comparable with those in sports, the programme 
could benefit the general population.”260
“This replicates and extends the work of Clarke and col‑
leagues and demonstrates that this CB (cognitive behav‑
ioural) prevention program can be reliably and effectively 
delivered in different settings by clinicians outside of the 
group who originally developed the intervention. The effect 
size was consistent with those of previously reported, single‑
site, indicated depression prevention studies and was robust 
across sites with respect to both depressive disorders and 
symptoms … In this generalisability trial, we chose a com‑
parison condition that is relevant to public health—usual 
care … The sample also was predominantly working class to 
middle class with access to health insurance. Given evidence 
that CB therapy can be more efficacious for adolescents from 
homes with higher incomes, it will be important to test the 
effects of this prevention program with more economically 
and ethnically diverse samples.”261
Explanation—External validity, also called generalisability 
or applicability, is the extent to which the results of a study 
can be generalised to other circumstances.262 Internal valid‑
ity, the extent to which the design and conduct of the trial 
eliminate the possibility of bias, is a prerequisite for external 
validity: the results of a flawed trial are invalid and the ques‑
tion of its external validity becomes irrelevant. There is no 
absolute external validity; the term is meaningful only with 
regard to clearly specified conditions that were not directly 
examined in the trial. Can results be generalised to an indi‑
vidual participant or groups that differ from those enrolled 
in the trial with regard to age, sex, severity of disease, and 
comorbid conditions? Are the results applicable to other 
drugs within a class of similar drugs, to a different dose, 
timing, and route of administration, and to different con‑
comitant therapies? Can similar results be expected at the 
primary, secondary, and tertiary levels of care? What about 
the effect on related outcomes that were not assessed in the 
trial, and the importance of length of follow‑up and duration 
of treatment, especially with respect to harms?263
External validity is a matter of judgment and depends on 
used for data collection and attribution of events should 
be described. For each study arm the absolute risk of each 
adverse event, using appropriate metrics for recurrent 
events, and the number of participants withdrawn due to 
harms should be presented. Finally, authors should pro‑
vide a balanced discussion of benefits and harms.42
Discussion
Item 20. Trial limitations, addressing sources of potential bias, 
imprecision, and, if relevant, multiplicity of analyses
Example—“The preponderance of male patients (85%) 
is a limitation of our study … We used bare‑metal stents, 
since drug‑eluting stents were not available until late dur‑
ing accrual. Although the latter factor may be perceived as a 
limitation, published data indicate no benefit (either short‑
term or long‑term) with respect to death and myocardial 
infarction in patients with stable coronary artery disease 
who receive drug‑eluting stents, as compared with those 
who receive bare‑metal stents.”253
Explanation—The discussion sections of scientific reports 
are often filled with rhetoric supporting the authors’ find‑
ings254 and provide little measured argument of the pros 
and cons of the study and its results. Some journals have 
attempted to remedy this problem by encouraging more 
structure to authors’ discussion of their results.255 256 For 
example, Annals of Internal Medicine recommends that 
authors structure the discussion section by presenting (1) a 
brief synopsis of the key findings, (2) consideration of pos‑
sible mechanisms and explanations, (3) comparison with 
relevant findings from other published studies (whenever 
possible including a systematic review combining the results 
of the current study with the results of all previous relevant 
studies), (4) limitations of the present study (and methods 
used to minimise and compensate for those limitations), and 
(5) a brief section that summarises the clinical and research 
implications of the work, as appropriate.255 We recommend 
that authors follow these sensible suggestions, perhaps also 
using suitable subheadings in the discussion section.
Although discussion of limitations is frequently omitted 
from research reports,257 identification and discussion of 
the weaknesses of a study have particular importance.258 
For example, a surgical group reported that laparoscopic 
cholecystectomy, a technically difficult procedure, had signif‑
icantly lower rates of complications than the more traditional 
open cholecystectomy for management of acute cholecysti‑
tis.259 However, the authors failed to discuss an obvious bias 
in their results. The study investigators had completed all the 
laparoscopic cholecystectomies, whereas 80% of the open 
cholecystectomies had been completed by trainees.
Authors should also discuss any imprecision of the 
results. Imprecision may arise in connection with several 
aspects of a study, including measurement of a primary 
outcome (see item 6a) or diagnosis (see item 4a). Perhaps 
the scale used was validated on an adult population but 
used in a paediatric one, or the assessor was not trained in 
how to administer the instrument.
The difference between statistical significance and clini‑
cal importance should always be borne in mind. Authors 
should particularly avoid the common error of interpreting a 
non‑significant result as indicating equivalence of interven‑
tions. The confidence interval (see item 17a) provides valu‑
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these points.277 Bayesian methods can be used to statistically 
combine the trial data with previous evidence.278
We recommend that, at a minimum, the discussion should 
be as systematic as possible and be based on a comprehen‑
sive search, rather than being limited to studies that support 
the results of the current trial.279
other information
Item 23. Registration number and name of trial registry
Example—“The trial is registered at ClinicalTrials.gov, 
number NCT00244842.”280
Explanation—The consequences of non‑publication of 
entire trials,281 282 selective reporting of outcomes within tri‑
als, and of per protocol rather than intention‑to‑treat analysis 
have been well documented.55 56 283 Covert redundant publi‑
cation of clinical trials can also cause problems, particularly 
for authors of systematic reviews when results from the same 
trial are inadvertently included more than once.284
To minimise or avoid these problems there have been 
repeated calls over the past 25 years to register clinical 
trials at their inception, to assign unique trial identifica‑
tion numbers, and to record other basic information about 
the trial so that essential details are made publicly avail‑
able.285‑288 Provoked by recent serious problems of with‑
holding data,289 there has been a renewed effort to register 
randomised trials. Indeed, the World Health Organisation 
states that “the registration of all interventional trials is 
a scientific, ethical and moral responsibility” (www.who.
int/ictrp/en). By registering a randomised trial, authors 
typically report a minimal set of information and obtain a 
unique trial registration number.
In September 2004 the International Committee of 
 Medical Journal Editors (ICMJE) changed their policy, saying 
that they would consider trials for publication only if they 
had been registered before the enrolment of the first partici‑
pant.290 This resulted in a dramatic increase in the number 
of trials being registered.291 The ICMJE gives guidance on 
acceptable registries (www.icmje.org/faq.pdf).
In a recent survey of 165 high impact factor medical 
journals’ instructions to authors, 44 journals specifically 
stated that all recent clinical trials must be registered as a 
requirement of submission to that journal.292
Authors should provide the name of the register and 
the trial’s unique registration number. If authors had not 
registered their trial they should explicitly state this and 
give the reason.
Item 24. Where the full trial protocol can be accessed, if available
Example—“Full details of the trial protocol can be found 
in the Supplementary Appendix, available with the full text 
of this article at www.nejm.org.”293
Explanation—A protocol for the complete trial (rather than 
a protocol of a specific procedure within a trial) is important 
because it pre‑specifies the methods of the randomised trial, 
such as the primary outcome (see item 6a). Having a pro‑
tocol can help to restrict the likelihood of undeclared post 
hoc changes to the trial methods and selective outcome 
reporting (see item 6b). Elements that may be important for 
inclusion in the protocol for a randomised trial are described 
elsewhere.294
There are several options for authors to consider ensur‑
the characteristics of the participants included in the trial, 
the trial setting, the treatment regimens tested, and the out‑
comes assessed.5 136 It is therefore crucial that adequate infor‑
mation be described about eligibility criteria and the setting 
and location (see item 4b), the interventions and how they 
were administered (see item 5), the definition of outcomes 
(see item 6), and the period of recruitment and follow‑up 
(see item 14). The proportion of control group participants 
in whom the outcome develops (control group risk) is also 
important. The proportion of eligible participants who refuse 
to enter the trial as indicated on the flowchart (see item 13) is 
relevant for the generalisability of the trial, as it may indicate 
preferences for or acceptability of an intervention. Similar 
considerations may apply to clinician preferences.264 265
Several issues are important when results of a trial are 
applied to an individual patient.266‑268 Although some vari‑
ation in treatment response between an individual patient 
and the patients in a trial or systematic review is to be 
expected, the differences tend to be in magnitude rather 
than direction.
Although there are important exceptions,268 therapies 
(especially drugs 269) found to be beneficial in a narrow range 
of patients generally have broader application in actual 
practice. Frameworks for the evaluation of external validity 
have been proposed, including qualitative studies, such as in 
integral “process evaluations”270 and checklists.271 Measures 
that incorporate baseline risk when calculating therapeutic 
effects, such as the number needed to treat to obtain one 
additional favourable outcome and the number needed to 
treat to produce one adverse effect, are helpful in assessing 
the benefit‑to‑risk balance in an individual patient or group 
with characteristics that differ from the typical trial partici‑
pant.268 272 273 Finally, after deriving patient centred estimates 
for the potential benefit and harm from an intervention, the 
clinician must integrate them with the patient’s values and 
preferences for therapy. Similar considerations apply when 
assessing the generalisability of results to different settings 
and interventions.
Item 22. Interpretation consistent with results, balancing benefits and 
harms, and considering other relevant evidence
Example—“Studies published before 1990 suggested that 
prophylactic immunotherapy also reduced nosocomial 
infections in very‑low‑birth‑weight infants. However, these 
studies enrolled small numbers of patients; employed var‑
ied designs, preparations, and doses; and included diverse 
study populations. In this large multicenter, randomised 
controlled trial, the repeated prophylactic administration of 
intravenous immune globulin failed to reduce the incidence 
of nosocomial infections significantly in premature infants 
weighing 501 to 1500 g at birth.”274
Explanation—Readers will want to know how the present 
trial’s results relate to those of other RCTs. This can best be 
achieved by including a formal systematic review in the 
results or discussion section of the report.83 275‑ 277 Such 
synthesis may be impractical for trial authors, but it is often 
possible to quote a systematic review of similar trials. A sys‑
tematic review may help readers assess whether the results 
of the RCT are similar to those of other trials in the same 
topic area and whether participants are similar across stud‑
ies. Reports of RCTs have often not dealt adequately with 
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reporting rcts that did not have a two group parallel 
design
The primary focus of the CONSORT recommendations is 
RCTs with a parallel design and two treatment groups. Most 
RCTs have that design, but a substantial minority do not: 
45% (233/519) of RCTs published in December 2000,16 
and 39% (242/616) in December 2006.17
Most of the CONSORT statement applies equally to 
all trial designs, but there are a few additional issues to 
address for each design. Before the publication of the 
revised CONSORT statement in 2001, the CONSORT Group 
decided to develop extensions to the main CONSORT state‑
ment relevant to specific trial designs. Extensions have 
been published relating to reporting of cluster randomised 
trials40 and non‑inferiority and equivalence trials.39 Lack 
of resources has meant that other planned extensions 
have not been completed; they will cover trials with the 
following designs: multiarm parallel, factorial, crossover, 
within‑person.
Authors reporting trials with a cluster design or using a 
non‑inferiority or equivalence framework should consult 
the CONSORT recommendations in addition to those in this 
document. Here we make a few interim comments about the 
other designs. In each case, the trial design should be made 
clear in both the main text and the article’s abstract.
Multiarm (>2 group) parallel group trials need the least 
modification of the standard CONSORT guidance. The flow 
diagram can be extended easily. The main differences from 
trials with two groups relate to clarification of how the study 
hypotheses relate to the multiple groups, and the consequent 
methods of data analysis and interpretation. For factorial tri‑
als, the possibility of interaction between the interventions 
generally needs to be considered. In addition to overall 
comparisons of participants who did or did not receive each 
intervention under study, investigators should consider also 
reporting results for each treatment combination.303
In crossover trials, each participant receives two (or 
more) treatments in a random order. The main additional 
issues to address relate to the paired nature of the data, 
which affect design and analysis.304 Similar issues affect 
within‑person comparisons, in which participants receive 
two treatments simultaneously (often to paired organs). 
Also, because of the risk of temporal or systemic carryo‑
ver effects, respectively, in both cases the choice of design 
needs justification.
The CONSORT Group intends to publish extensions 
to CONSORT to cover all these designs. In addition, we 
will publish updates to existing guidance for cluster ran‑
domised trials and non‑inferiority and equivalence trials to 
take account of this major update of the generic CONSORT 
guidance.
discussion
Assessment of healthcare interventions can be misleading 
unless investigators ensure unbiased comparisons. Ran‑
dom allocation to study groups remains the only method 
that eliminates selection and confounding biases. Non‑ran‑
domised trials tend to result in larger estimated treatment 
effects than randomised trials.305 306
Bias jeopardises even RCTs, however, if investigators 
carry out such trials improperly.307 A recent systematic 
ing their trial protocol is accessible to interested readers. As 
described in the example above, journals reporting a trial’s 
primary results can make the trial protocol available on 
their web site. Accessibility to the trial results and protocol 
is enhanced when the journal is open access. Some journals 
(such as Trials) publish trial protocols, and such a publication 
can be referenced when reporting the trial’s principal results. 
Trial registration (see item 23) will also ensure that many trial 
protocol details are available, as the minimum trial charac‑
teristics included in an approved trial registration database 
includes several protocol items and results (www.who.int/
ictrp/en). Trial investigators may also be able to post their 
trial protocol on a website through their employer. Whatever 
mechanism is used, we encourage all trial investigators to 
make their protocol easily accessible to interested readers.
Item 25. Sources of funding and other support (such as supply of 
drugs), role of funders
Examples—“Grant support was received for the interven‑
tion from Plan International and for the research from 
the Wellcome Trust and Joint United Nations Programme 
on HIV/AIDS (UNAIDS). The funders had no role in study 
design, data collection and analysis, decision to publish, 
or preparation of the manuscript.”295
“This study was funded by GlaxoSmithKline Pharmaceu‑
ticals. GlaxoSmithKline was involved in the design and con‑
duct of the study and provided logistical support during the 
trial. Employees of the sponsor worked with the investigators 
to prepare the statistical analysis plan, but the analyses were 
performed by the University of Utah. The manuscript was 
prepared by Dr Shaddy and the steering committee mem‑
bers. GlaxoSmithKline was permitted to review the manu‑
script and suggest changes, but the final decision on content 
was exclusively retained by the authors.”296
Explanation—Authors should report the sources of 
funding for the trial, as this is important information for 
readers assessing a trial. Studies have showed that research 
sponsored by the pharmaceutical industry are more likely 
to produce results favouring the product made by the com‑
pany sponsoring the research than studies funded by other 
sources.297‑300 A systematic review of 30 studies on funding 
found that research funded by the pharmaceutical indus‑
try had four times the odds of having outcomes favouring 
the sponsor than research funded by other sources (odds 
ratio 4.05, 95% confidence interval 2.98 to 5.51).297 A 
large proportion of trial publications do not currently 
report sources of funding. The degree of underreporting 
is difficult to quantify. A survey of 370 drug trials found 
that 29% failed to report sources of funding.301 In another 
survey, of PubMed indexed randomised trials published in 
December 2000, source of funding was reported for 66% 
of the 519 trials.16
The level of involvement by a funder and their influence 
on the design, conduct, analysis, and reporting of a trial 
varies. It is therefore important that authors describe in 
detail the role of the funders. If the funder had no such 
involvement, the authors should state so. Similarly, authors 
should report any other sources of support, such as supply 
and preparation of drugs or equipment, or in the analysis 
of data and writing of the manuscript.302
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us know of their support. The ultimate benefactors of these 
collective efforts should be people who, for whatever rea‑
son, require intervention from the healthcare community.
We are grateful to Frank Davidoff and Tom Lang for their involvement in the 
2001 version of CONSORT explanation and elaboration document. A special 
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